| Home | About | Investor Relations | News | Products | Alliances | |||||||
| ||||||||||||
| Corporate Profile |
|
Executive Management |
|
Board of Directors |
|
Investor Presentations |
| Stock Price |
| SEC Filings |
| Sarbanes Compliance |
| Current |
| Archives |
| Overview |
| Our Facility |
| Compact Photonic Explorer (CPE)Diagnostic Pill |
| CD Ratiometer |
| CD Scan |
| CD Map |
| Photo Gallery |
| FDA Clinical Trials |
| Research & Development |
|
Archive of Press Releases |
| ||||||||
|
||||||||
|
|
|
||||||||||||||||||||||||||||||||||||||||||||
|
April 03, 2006: FDA Approves Mediscience Optical Biopsy Device Multi-Center Pilot Study for Molecular Cancer Detection of the Cervix March 07, 2006: Mediscience and Alfanix Technology in Alliance to Build and Test Sophisticated Photonics Cancer Diagnostics Devices January 05, 2006: Mediscience Inc. Files Investigational Device Exemption (IDE) Application with the Center for Devices and Radiological Health of the FDA November 28, 2005: Mediscience Technology Corp. Announces Board Additions November 10, 2005: Mediscience Technology Corp. Names Frank Benick, CPA Chief Financial Officer October 26, 2005: Mediscience Technology Corp. and Infotonics Technology Center Inc. Report "Compact Photonic Explorer" (CPE), "Pill Camera" Progress September 6, 2005: Mediscience Technology Engages Investment Bankers Aug 17, 2005: Mediscience Technology Corp. Announces Its Successful Closing on August 16, 2005 of a $1.525 Million Dollar Private Placement July 26, 2005: Mediscience Technology Corp. Sets Meeting Date with FDA to Review Pre-IDE Submission Regarding Cancer Detection Device; Mediscience to Meet with FDA on August 18, 2005 to Discuss Its CD-Ratiometer Dev May 12, 2005: Mediscience Technology Corp. Announces Pre-IDE Meeting Request for CD-Ratiometer, a Cancer Detection Device April 11, 2005: Mediscience Technology Corp. Developing Cancer Detection Instrument for Analyzing Surgical Breast Tissue Specimens at Point-of-Care January 27, 2005: Mediscience Technology Corp. Names Dr. Julian Kim as consultant for the development of the jointly proposed micro-endoscopic device utilizing MTC proprietary technology for native fluorescence molecular measurements of breast ducts December 9, 2004: Mediscience Technology Corp. Announces Completion of Development of Its Optical Biopsy Cancer Diagnostic Ratiometer and Submission to the FDA of the Pre-IDE Briefing Materials November 11, 2004: Mediscience Technology Corp./Medi-photonics Development Company LLC and Infotonics Technology Center Announce Their Definitive Collaborative R&D Equity Agreement September 8, 2004: Infotonics Technology Center and Medi-photonics Development Company LLC announced their intent to agree to jointly develop the "Compact Photonic Explorer". Infotonics is a consortium that includes Corning, Inc., Eastman Kodak Company, and Xerox Corporation, and several New York State universities. Infotonics is a world-class research and development facility established to enable the rapid commercialization of new high tech products. August 2, 2004: Mediscience Technology Corp. Prevents Unauthorized Listing of Company Stock on Berlin-Bremen Stock Exchange June 15, 2004: New CD-ROM from Optical Society of America offers comprehensive collection of papers on biomedical optical biopsy. To order the CD-ROM Biomedical Optical Biopsy from the Optical Society of America please go to www.osa.org/pubs/bookstore2 May 2, 2004: Mediscience Technology Corp. (otc-mdsc) Announces Project Agreement For Development Of Cancer Detection And Diagnosis Device With Research Foundation Of The City University Of New York April 14, 2004: Mediscience Technology Corp. (otc-mdsc) Names Robert G. Pinco to Advisory Council Feb 2, 2004: Mediscience Technology Corp. (otc-mdsc) announces the successful closing of a $1.5 Million dollars Private Placement as of February 1, 2004 Dec 17, 2003: the FDA qualified the Mediscience Technology Corp. for both reduced or waived FDA fees for its 2004 medical device 510K market approval submissions Dec 3, 2003: Mediscience Technology Corp. OTC-MDSC Secures Exclusive World-Wide License to US Molecular Imaging Patent Applications, Expected to Extend Core Technology Additional 17+ Years Nov. 24, 2003: Breakthrough in Detecting Cancerous Tissue via Stokes Shift Emission Spectroscopy July 16, 2003: CCNY Receives $6 Million NASA Grant To Enhance Photonics Research June 4, 2003: Mediscience Technology Announces Formation Of New Subsidiary To Develop Potential Clinical Application For Non-Invasively Diagnosis Of Prostate Cancers April 28, 2003: Mediscience Technology Appoints Michael Engelhart President and Chief Operating Officer Effective Immediately March 14, 2003: Mediscience Technology Appoints Michael Engelhart To The Board Of Directors January 22, 2003: Mediscience Technology Selects THM Group For Commercialization Phase Of Cancer Detection Technology June 30, 2002: The Research Foundation City University Of New York (Rfcuny) Acquires Major Equity Position In Mediscience Technology Corp. July 12, 2001: Mediscience Technology Selects Mr. Sidney Braginsky as new President and COO March. 8, 1999: FDA Approves Phase II in Vivo use of Medisience CD-Scan Optical System as Non-Significant Risk Device in Yale University/Mediscience significant Womens Health Study March. 24, 1999: Mediscience Cd-Scan Effective in Cornell/New York Medical Barrett's Esophageal Relux Study in Distinguishing Normal Esophageal Tissue From Barrett's or Adenocarcinoma June 3, 1997: MEDISCIENCE US PATENT ISSUED: Techniques to detect cellular malignancy for PAP SMEAR type samples March 19, 1997: Mediscience Announces "Incubator" Space on Campus Jan. 8, 1997: Mediscience Announces FDA "IDE" Approval FDA APPROVES MEDISCIENCE OPTICAL BIOPSY DEVICE MULTI-CENTER PILOT STUDY FOR MOLECULAR CANCER DETECTION OF THE CERVIX CHERRY HILL, N.J., Apr 03, 2006 -- Mediscience Technology, Corp. (OTCBB:MDSC.OB) announced today: The Food and Drug Administration on March 29, 2006 approved as a "Non-significant risk device study the Company's multi-center pilot study to establish the safety and parameters of efficacy of its proprietary Optical Biopsy Device (CD-R) for cancer detection of the cervix preliminary to a pivotal study" expected to bring this molecular algorithmic specific technology to market. Dr Robert Schiff of Schiff & Company/ Regulatory Affairs advised "The FDA has notified Mediscience that the device (CD-R) is a non-significant risk device. We can therefore commence the Pilot study at any time observing the regulations governing patient consent and institutional IRB approval. The FDA has also given us comments and suggestions which will assist Mediscience in its clinical studies." Peter Katevatis Chairman/CEO: "The main objectives of this pilot study are to determine efficacy; the clinical sensitivity and clinical specificity (ability for the device to distinguish between tissues that are normal, benign, precancerous low grade, precancerous high grade, CIS and cancer) by comparing the device real-time results to the PAP test and biopsy; and assess any adverse events based on Good Clinical Practices. Frequency, type and intensity of clinical adverse events will also be evaluated. Assuming the results of this initial efficacy and safety study are satisfactory, in the detection of cervical cancer precursors i.e. (pre-cancerous cells), indications of possible cancer development the Company will continue into its pivotal study where the principal endpoint will be proof of effectiveness in a statistically significant sample of subjects." Dr. Robert Alfano (pioneer in optical biopsy, co-founder and advisor to Mediscience Technology and President of Alfanix LTD): "This FDA approval advances Mediscience to the next level towards commercialization and is a major step in advancing diagnostic medicine using fluorescence light. Alfanix plans to help Mediscience with its CD-R platform technology in the medical cancer areas and possibly expanding the market into Latin America." Mediscience Technology Corporation is engaged in the design and development of fluorescence-based optical biopsy platform system that uses the properties of light and its molecular interaction with tissue to aid in the diagnosis of physiological change and cancer. The Mediscience IP technology platform is based on imaging native fluorescence from the surface of an optically excited tissue and offers paradigm shift potential as a noninvasive, in-vivo cancer diagnostic because of the unique ability to detect/distinguish abnormalities in molecular tissue composition and/or structure. Further, the development of a Mediscience cost effective, high resolution commercial imaging system for real-time in-vivo diagnostics has the potential to vastly improve upon current standards of diagnostic sensitivity and specificity. (e.g. Cervical cancer a highly preventable cancer with early detection and removal of pre-cancerous cervical lesions) About Mediscience Technology Mediscience Technology Corporation and its New York subsidiary, Medi-photonics Development Company LLC, are engaged in the design, development and commercialization of medical devices that detect cancer and physiological change using frequencies of light that are emitted, scattered and absorbed to distinguish malignant, pre-cancerous or benign tissues from normal tissues. Mediscience's exclusive protected noninvasive technology combines the advantages of real-time results with enhanced diagnostic sensitivity and specificity compared with other methods of cancer detection. www.infotonics.org/ResearchProjects/CompactPhotonicExplorers.asp Mediscience 8-K filing dated April 4, 2006 New England Journal of Medicine 7-29-04 (capsule endoscopic technology) CITIGROUP/Smith Barney Analyst Report 10-1-2004 by Peter Bye. Page 20 (Mediscience/Infotonics) Alfanix LTD Dr Robert Alfano 917 969 2209 info@alfanix.com MEDISCIENCE AND ALFANIX TECHNOLOGY IN ALLIANCE TO BUILD AND TEST SOPHISTICATED PHOTONICS CANCER DIAGNOSTICS DEVICES CHERRY HILL, N. J.--March 7, 2006-- Mediscience Technology Corp. (OTCBB:MDSC) (Mediscience) and Alfanix Technology, Ltd. (ATL) are pleased to announce an alliance to construct sophisticated photonics devices for cancer diagnostics, such as the Cancer Diagnostic Ratiometer (CD-R); and to introduce the devices into Latin America for testing on human subjects. CD-Rs use light fluorescence to distinguish between cancerous and non-cancerous tissues to obtain a more accurate in situ optical PAP test. CD-R results are immediate, whereas diagnosis via conventional PAP smears takes approximately one week. While CD-Rs are seen as a supplement for conventional PAP smears initially, they may eventually serve as a substitute. The alliance was announced jointly by Mr. Peter Katevatis Esq., Chairman and CEO of Mediscience, and Dr. Robert R. Alfano, President and CEO of ATL. The alliance will be funded by Mediscience, a public company trading on the OTC Bulletin Board under the symbol "MDSC." As part of the alliance, ATL will oversee the construction for Mediscience of CD-R Beta units for use in clinical testing. At least two will be used for clinical tests in the Dominican Republic under the supervision of ATL; and at least two will be used for similar trials in the United States under the supervision of Mediscience. The objective is to obtain algorithms in order to evaluate and improve the efficacy of CD-Rs on human subjects. With a high index rate of GYN cancer among Latin America's female population, there is an urgent need for a more accurate approach to detect and diagnose the disease. The ability to diagnose cancer in real time, offers the added benefit of being able to provide life-saving treatment for cervical cancer that otherwise might not be available because of the difficulty of getting many Latin American women to return for treatment after providing them with a delayed diagnosis of malignancy based on the examination of a PAP smear. ATL is a New York State for-profit company focusing on developing, building and selling photonics-based medical and non-medical devices, Cr laser crystals, novel compact lasers, and photonics related technology. ATL's mission is to help companies develop and market photonics products; and assist with testing and marketing of these products in the United States and internationally with an emphasis on Latin America. ATL is developing a network of doctors and hospitals in Latin America, starting with the Dominican Republic, for the introduction, testing, and marketing of photonics-based medical products for detection and diagnosis of cancer of the GYN tract, breast, and skin. In return for developing and introducing a marketable product for companies under contract, ATL will receive an agreed upon royalty and/or a percentage interest in either the product-line or the company. The alliance between ATL and Mediscience includes the identification of and subsequent training of medical teams in the Dominican Republic to use the CD-R system. Medical teams will be composed of an oncologist, pathologist and medical technician. Dr. Alfano stated that, "this Agreement will enhance the development of the CD-R and other sophisticated photonics devices that have the potential to become important new cancer diagnostic tools. It will also help to bring Mediscience to the next level in marketing cancer fluorescence devices." Mr. Katevatis added, " this extraordinary Alliance contractually endows Mediscience with on-going technical resources, not available in any other single individual or un- experienced entity, to be applied to our CD-R, technology, our FDA clinicals and subsequent sequential market entry of additional Mediscience Platform applications." Dr. Alfano is the inventor of fluorescence technology and the developer of the CD-R. He noted that the Latin American and Dominican Republic connections regarding the CD-R and other Photonics products will also bring high technology and valuable training to those regions in a number of fields, including tunable lasers, laser crystals technology, and water pollution detection based on the fluorescence of bacteria. Mediscience and ATL are clients of CUNY's New York State Center for Advanced Technology in Photonics Applications. The CUNY-CAT develops and disseminates knowledge in photonics technology in order to promote New York State economic development for the medical, biological, industrial and military sectors; and provides New York State companies with research services, including infrastructure and business development. INVESTOR NOTICE: Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include among other things, the availability of financing, the company's ability to implement its herein indicated present CD-R and long-range business plan for various other applications of its technology; the company's ability to enter into successful agreements with any necessary or desirable marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary US or Latin American Country regulatory or other approvals/ clearances applicable to applications of the company' technology; and management of growth and other risked and uncertainties that may be detailed from time to time in the company's reports filed with the Securities and Exchange Commission. This disclosure is intended to satisfy: SEC Section 6,6.01 Regulation FD, disclosure and Section 7 and 7.0 as well as all applicable and presently effective Sarbanes-Oxley disclosure requirements under Regulation G. Ref: 8-K filing dated March 6, 2006 CONTACT: Mediscience Technology Corp. MEDISCIENCE INC. FILES INVESTIGATIONAL DEVICE EXEMPTION (IDE) APPLICATION WITH THE CENTER FOR DEVICES AND RADIOLOGICAL HEALTH OF THE FDA CHERRY HILL, N.J., Jan 05, 2006 -- MEDISCIENCE TECHNOLOGY CORP. -- Mediscience (MTC) (OTCBB:MDSC) reported that it has filed an Investigational Device Exemption (IDE) application with the Center for Devices and Radiological Health of the FDA. The filing is subject to evaluation by the FDA to determine when a proposed human clinical pilot study of the Company's Cervical Cancer Detection Radiometer (CD-R) may begin. Mediscience Chairman Peter Katevatis Esq. stated, "This anticipated pilot study for the initiation of MTC adjunct clinical trials brings the Company one step closer to commercialization of its broad patented Optical Biopsy technology platform applications. We further believe that any and all acquired FDA/MTC approvals will add significant synergistic and applicable value to our Joint effort with INFOTONICS RESEARCH CORP. in the development of the 'Compact Photonic Explorer' (CPE), or 'pill camera,' an ingestible photonic pill that would enable physicians to detect early stage cancer of the complete auto-digestive tract with our embedded patented Optical Biopsy technology platform." The clinical objectives are to demonstrate the device's ability to distinguish between tissues that are normal, benign, precancerous low grade, precancerous high grade, and cancerous. The device results will be compared to the PAP test and tissue biopsy and will be evaluated for clinical adverse events. The pilot study will enroll 400 patients in a multi-center study of sensitivity and specificity of MDSC's precancer/cancer detection ratiometer (CDR) device. Two groups of 50-75 patients each will be tested to define the spectral characteristics of the normal and cancerous cervix (histology). The remaining population will be tested to define intermediary states between normal and various stages of cancer. Mediscience and its New York subsidiary, Medi-photonics Development Company LLC, is engaged in the design, development and commercialization of medical devices that aid in the molecular diagnosis of cancer and physiological change using frequencies of light that are emitted, scattered and absorbed to distinguish malignant, precancerous, or benign tissues from normal tissues. The Company's exclusive protected IP non-invasive technology combines the advantages of real-time results with enhanced diagnostic sensitivity and specificity compared with other methods of cancer detection and offers a paradigm shift unique ability to detect molecular abnormalities in tissue composition and/or structure with out patient health hazard. The Infotonics Technology Center Inc. (Infotonics) operates New York State's Center of Excellence in Photonics and Microsystems. Infotonics is structured as a consortium whose founding participants include Corning, Inc., Eastman Kodak Company, and Xerox Corporation. The Rochester Regional Photonics Cluster is an industrial partner, and academic participants include some 20 New York State colleges and universities. Infotonics' goal is to establish a unique, world-class research and development facility to enable rapid commercialization of new products. This initiative will provide major benefits to the region, including creation of jobs and attraction of new companies and investment revenue. Infotonics is a present and significant shareholder of MTC. See Web sites: www.infotonics.org/ResearchProjects/CompactPhotonicExplorers.asp See Mediscience 8-K filing dated Sept 8 2005 (MTC and INFOTONICS to jointly develop the "Compact Photonic Explorer" (CPE), or "pill camera") See New England Journal of Medicine 7-29-04 (general results of developing capsule endoscopic technology) INVESTOR NOTICE: Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the parties/company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include among other things, FDA approvals, the availability of financing, the parties/company's ability to implement its long-range business plan for various applications of its technology; the company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary US regulatory clearances, including but not limited to FDA, applicable to various applications/submissions of the company' technology; and management of growth and other risked and uncertainties that may be detailed from time to time in the parties/company's reports filed with the Securities and Exchange Commission. This disclosure is intended to satisfy: SEC Section 6, 6.01 Regulation FD, disclosure and Section 7 and 7.0 as well as all applicable and presently effective Sarbanes-Oxley disclosure requirements under Regulation G. SOURCE: Mediscience Technology Corp. Mediscience Technology Corp. Michael Engelhart, 201-818-0050 Mengelhart@medisciencetech.com or Peter Katevatis Esq. 215-485-0362 metpk@aol.com or Infotonics Technology Center Inc. David Smith, 585-919-3000 david.r.smith@infotonics.org MEDISCIENCE TECHNOLOGY CORP. ANNOUNCES BOARD ADDITIONS CHERRY HILL, N.J., Nov 10, 2005 -- Mediscience Technology Corp. (OTCBB:MDSC) announced, effect immediately, Joseph Franchetti, Dr. Anil Rastogi and Sidney Braginsky have joined the Mediscience Board as independent directors (see 8-K filing November 28, 2005 for complete and specific detailed CV's of the three. Joseph Franchetti: extensive executive corporate experience in the medical device industry as CEO, President, COO of start-up and NYSE companies. Responsible for product development management and distribution, e.g. Technicon Corporation, Tarrytown, New York 1970 - 1979 Vice-President/General Manager (now Bayer Corporation), Narco Scientific, Pennsylvania former (NYSE) public company Executive Vice-President and General Manager, Colin Medical Instruments Corporation, San Antonio, Texas CEO, President, Director responsible for starting, building all North/South American operations. Japanese owned world-leader in non-invasive blood pressure and vital signs diagnostic and monitoring medical devices Dr. Anil Rastogi: A senior executive with diverse leadership experience in several industries & in academic environment managing technology-driven businesses, start-up ventures & successfully completing IPO. Demonstrated success at commercialization of technology, bringing products from inception to market. Strong skills in establishing global strategic partners, strong organization development skills with bottom-line focus and a profit orientation. International experience in European and Pacific Rim markets. e.g. MEAD IMAGING, Dayton, Ohio 1987-1991 President, Cycolor Division 1989-1991, NOMOS Corporation, Sewickley, Pennsylvania leading supplier of radiation therapy treatment planning software and systems for cancer patients 1998-2002 President & Chief Executive Officer, OWENS-CORNING FIBERGLAS CORPORATION, Toledo, Ohio 1969-1987 Director, Corporate Diversification Portfolio 1983-1987 Sidney Braginsky: senior executive with diverse leadership experience in several industries was with Olympus Optical Ltd., Executive Vice-President and COO of the Olympus Scientific Products Group, a multi-national corporation 30 years in senior corporate and executive positions including serving from 1991 to 2001 as chief executive officer, and from 1999 to July 2001 as president and chief executive officer of Olympus America and executive vice-President and COO of the Olympus Scientific Products Group. Mediscience Chief Executive Officer Peter Katevatis Esq. stated, "The three Board members and the recent employment of Mr. Benick CPA as Company CFO provide Mediscience significant and valuable depth of corporate and market experience to properly deploy specific applications of our IP Optical Biopsy platform technology." e.g.
About Mediscience Technology Corp. Mediscience Technology Corporation and its New York subsidiary, Medi-photonics Development Company LLC, are engaged in the design, development and commercialization of medical devices that detect cancer and physiological change using frequencies of light that are emitted, scattered and absorbed to distinguish malignant, precancerous, or benign tissues from normal tissues. Mediscience's exclusive protected noninvasive technology combines the advantages of real-time results with enhanced diagnostic sensitivity and specificity compared with other methods of cancer detection. Investor Notice Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks and uncertainties including market conditions and FDA approval, which is required before the Camera Pill or the CD Ratiometer can be sold or licensed for use in the United States. This press release is intended to comply with Rule 135c promulgated under the Securities Act of 1933. 8-K filing dtd November 28, 2005 (directors) 8-K filing dtd November 8, 2005 (Chief Financial Officer) www.infotonics.org/ResearchProjects/CompactPhotonicExplorers.asp New England Journal of Medicine July-29-2004 (capsule endoscope technology) CITIGROUP/Smith Barney Analyst Report 10-1-2004 see Pg. 20 (MTC/Info tonics) SOURCE: Mediscience Technology Corp. Mediscience Technology Corporation Michael Engelhard, 201-818-0050 mengelhart@mediscience.com or Peter Katevatis Esq., 215-485-0362 metpk@aol.com MEDISCIENCE TECHNOLOGY CORP. NAMES FRANK BENICK, CPA CHIEF FINANCIAL OFFICER CHERRY HILL, N.J., Nov 10, 2005 -- Mediscience Technology, Corp. (OTCBB:MDSC) announced today that Mr. Frank Benick, CPA has joined the company as its Chief Financial Officer effective November 15, 2005. Mr. Benick has extensive CFO experience in the management and supervision of public company accounting with specific expertise in all phases of accounting, and related SEC/Sarbanes matters. His consultant responsibilities will include advice/oversight of Mediscience management including but not limited to the filing of SEC Forms 1Q-Q, 10-K, weekly and monthly financial statements, installation of computer and accounting controls for cash, payroll, invoice payment, gross profit analysis and budgets. The text of his employment agreement and CV is filed as Exhibit 99.1 to the Company's SEC 8-K filed November 10, 2005. About Mediscience Technology Mediscience Technology Corporation and its New York subsidiary, Medi-photonics Development Company LLC, is engaged in the design, development and commercialization of medical devices that detect cancer and physiological change using frequencies of light that are emitted, scattered and absorbed to distinguish malignant, precancerous, or benign tissues from normal tissues. Mediscience's exclusive protected noninvasive technology combines the advantages of real-time results with enhanced diagnostic sensitivity and specificity compared with other methods of cancer detection. Investor Notice Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the parties/company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include among other things, the availability of financing, the parties/ company's ability to implement its long-range business plan for the joint or independent development of various applications of its technology/ IP; the company's ability to enter into future agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary US regulatory i.e. FDA clearances applicable to applications of the company's technology; and management of growth and other risked and uncertainties that may be detailed from time to time in the parties/company's reports filed with the Securities and Exchange Commission. This disclosure is intended to satisfy: SEC Section 6, 6.01 Regulation FD, disclosure and Section 7 and 7.0 as well as all applicable and presently effective Sarbanes-Oxley disclosure requirements under Regulation G. 8-K filing dated November 8, 2005. www.infotonics.org/ResearchProjects/CompactPhotonicExplorers.asp Mediscience SB-2 registration filing dated Dec. 23, 2004 effective Jan 12, 2005 New England Journal of Medicine July-29-2004 (capsule endoscope technology) CITIGROUP/Smith Barney Analyst Report 10-1-2004 see Pg. 20 (MTC/Info tonics) SOURCE: Mediscience Technology Corporation Mediscience Technology Corporation Michael Engelhard, 201-818-0050 mengelhart@mediscience.com or Peter Katevatis Esq., 215-485-0362 metpk@aol.com MEDISCIENCE TECHNOLOGY CORP. AND INFOTONICS TECHNOLOGY CENTER INC. REPORT "COMPACT PHOTONIC EXPLORER" (CPE), "PILL CAMERA" PROGRESS CHERRY HILL, N.J., Oct 26, 2005--Infotonics Technology Center Inc. and Medi-photonics Development Company LLC, a subsidiary of Cherry Hill New Jersey-based Mediscience Technology Corp. a developer of proprietary non-invasive imaging technology for molecular detection of cancer and physiological change, (MTC), (OTCBB- "MDSC"), announce that their joint development of the "Compact Photonic Explorer" (CPE), or "pill camera," for medical applications utilizing (MTC) optical biopsy IP, to advance to a production prototype, (manufacturable, meeting all "market-ready" product performance specs. on a best case scenario and an aggressive time-line) to be delivered in 12-18 months on an estimated R&D investment of $3 - 5M. The parties announced their agreement to jointly develop the Compact Photonic Explorer (CPE), or pill camera, on September 8, 2004 The initial focus of the project --developing a (CPE) " that would detect cancer and monitor body functions". The goal - to create an ingestible photonic pill that would enable physicians to detect early stage cancer of the complete auto-digestive tract. Such a non-invasive device would lead to reduced mortality and health care costs, and would significantly increase the number of people who could be screened for this type of cancer. The proof-of-concept research for the (CPE), led by Dr. Robert Alfano and his team at City University of New York (CUNY), has been successful based upon an on-going four-year multidisciplinary/multi-institutional effort to develop miniature devices that use light to remotely monitor the health of various environments in collaboration with researchers at Cornell, SUNY Albany, SUNY Binghamton, RPI, Rochester Institute of Technology, the University of Rochester, and Boston University." (Infotonics) is a consortium whose founding participants include Corning, Inc., Eastman Kodak Company, and Xerox Corporation, a not-for-profit corporation that operates New York State's Center of Excellence in Photonics and Microsystems. (MTC) Chairman/CEO Peter Katevatis stated "this joint effort between Medi-photonics and Infotonics is a synergistic and strategic fit leveraging the Center's unique nano-technology capabilities, resources and (MTC) optical biopsy IP. This project has enhanced (MTC) proprietary non-invasive imaging "optical biopsy" technology for molecular detection of cancer and physiological change and the Company's desire to commercialize its patented technology." David R. Smith President & CEO (Infotonics) states "Capital investment would be required to establish the pilot production capability (e.g initial units for FDA clinicals) and the amount of capital funds would vary greatly with the production capacity required. From an R&D perspective we would proceed/participate in presentations etc together to seek competitive grant funding from NIH, and other available sources public and/or private. With our assistance and support Medi-Photonics LLC/Mediscience would at some early juncture contact/meet with the Empire State Development agency and Ontario County in New York State who have from project inception expressed significant New York State economic interest in the Rochester New York State area with significant financial incentives for the Compact Photonics Explorer (CPE) project should the project locate here. Infotonics is committed to support the appropriate path forward for Medi-Photonics LLC/Mediscience business success." About the Infotonics Center (Infotonics) is a not-for-profit corporation that operates New York State's Center of Excellence in Photonics and Microsystems. Infotonics is structured as a consortium whose founding participants include Corning, Inc., Eastman Kodak Company, and Xerox Corporation. The Rochester Regional Photonics Cluster is an industrial partner, and academic participants include some 20 New York State colleges and universities. Infotonics' goal is to establish a unique, world-class research and development facility to enable rapid commercialization of new products. This initiative will provide major benefits to the region, including creation of jobs and attraction of new companies and investment revenue. About Mediscience Technology Mediscience Technology Corporation and its New York subsidiary, Medi-photonics Development Company LLC, is engaged in the design, development and commercialization of medical devices that detect cancer and physiological change using frequencies of light that are emitted, scattered and absorbed to distinguish malignant, precancerous, or benign tissues from normal tissues. Mediscience's exclusive protected IP noninvasive technology combines the advantages of real-time results with enhanced diagnostic sensitivity and specificity compared with other methods of cancer detection. See Web sites: www.infotonics.org/ResearchProjects/CompactPhotonicExplorers.asp See Mediscience 8-K filing dated September 8, 2004 See New England Journal of Medicine 7-29-04 (general results of developing capsule endoscopic technology) CITIGROUP/Smith Barney Analyst Report 10-1-2004 by Peter Bye. Page 20 (GIVEN IMAGING-Mediscience/Infotonics) INVESTOR NOTICE: Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the parties/ company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include among other things, the availability of financing, the parties/ company's ability to implement its long-range business plan for various applications of its technology; including but not limited to that expressed herein; the company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary US regulatory clearances applicable to applications of the company' technology; and management of growth and other risked and uncertainties that may be detailed from time to time in the parties/ company's reports filed with the Securities and Exchange Commission. This disclosure is intended to satisfy: SEC Section 6, 6.01 Regulation FD, disclosure and Section 7 and 7.0 as well as all applicable and presently effective Sarbanes-Oxley disclosure requirements under Regulation G. SOURCE: Mediscience Technology Corp. Infotonics Technology Center, Inc David R. Smith david.r.smith@infotonics.org or Mediscience Technology Corp. Peter Katevatis, 215-485-0362 metpk@aol.com MEDISCIENCE TECHNOLOGY ENGAGES INVESTMENT BANKERS CHERRY HILL, N.J.--Mediscience Technology Corp. (OTCBB:MDSC) announced today that it has engaged the services of a United States investment banking firm as its exclusive placement agent for a proposed private placement on a best efforts basis of between $6 million and $10 million. The private placement is expected to commence during the fourth calendar quarter of 2005. Mediscience Chief Executive Officer Peter Katevatis stated, "We intend to use the net proceeds of the proposed private placement to fund our ingestible optical biopsy capable 'Camera Pill' (designed to distinguish cancerous, pre-cancerous, or benign tissues from normal tissue) and initiate FDA clinical trials for our CD Ratiometer(TM), a medical device designed to detect cervical cancer on a molecular level and for general corporate purposes." The proposed Private Placement will not be registered under the Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirement. About Mediscience Technology Corp. Mediscience Technology Corporation and its New York subsidiary, Medi-photonics Development Company LLC, are engaged in the design, development and commercialization of medical devices that detect cancer and physiological change using frequencies of light that are emitted, scattered and absorbed to distinguish malignant, precancerous, or benign tissues from normal tissues. Mediscience's exclusive protected noninvasive technology combines the advantages of real-time results with enhanced diagnostic sensitivity and specificity compared with other methods of cancer detection. Investor Notice Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks and uncertainties including market conditions and FDA approval, which is required before the Camera Pill or the CD Ratiometer can be sold or licensed for use in the United States. This press release is intended to comply with Rule 135c promulgated under the Securities Act of 1933. Mediscience Technology Corp. Michael Engelhart, 201-925-5077 mengelhart@mediscience.com or Peter Katevatis Esq., 215-485-0362 metpk@aol.com MEDISCIENCE TECHNOLOGY CORP. ANNOUNCES ITS SUCCESSFUL CLOSING ON AUGUST 16, 2005 OF A $1.525 MILLION DOLLAR PRIVATE PLACEMENT CHERRY HILL, N.J., Aug 17, 2005 -- Mediscience Technology Corp. (MTC), (OTCBB- "MDSC"), a developer of imaging technology for molecular detection of cancer and physiological change, announced that on August 16, 2005 it privately closed its SEC Reg. "D" Private Placement with net cash infusion to the Company of $1.525 million dollars. And attached warrants totaling $3 million dollars exercisable at $1.00 per share.
Investment basis--SEC Reg. D Private placement: "The minimum subscription to August 15, 2005 this offerings closing, is $25,000 for each UNIT of Mediscience Common restricted per SEC Rule 144, each individual dollar investment to be no less than $25,000 for a minimum subscription of fourteen (14) UNITS ($350.000) to a maximum subscription of one hundred sixty (160) UNITS ($4,000,000). Each UNIT share of unregistered MTC common valued at fifty ($.50) cents per share with one warrant per share attached to purchase one additional share at one dollar ($1.00) a share of Mediscience common share restricted per SEC Rule 144, said warrant expiring by its terms on August 1, 2007. The Company reserved the right to accept or reject any subscription tendered, to August, 15, 2005 closing this offering in whole or in part on a smaller number of UNITS subscribed than the maximum of 160." Chairman/CEO Peter Katevatis stated, "This funding will allow the company to move forward in our effort to commercialize our Optical Biopsy technology and immediately prepare and initiate clinical trials for Cervical cancer applications supportive to our August 18, 2005 meeting with the FDA." SEE 8-K filing of registrants REG D filing dated August 16, 2005 Web Page: MEDISCIENCETECH.com www.cunyphotonics.com 8-K filing dated September 8, 2004 New England Journal of Medicine 7-29-04 (developing capsule endoscopy) CITY GROUP/Smith Barney Analyst Report 10-01-2004 by Peter Bye, page 20 (MTC/INFOTONICS) INVESTOR NOTICE: Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include among other things, the availability of financing, the company's ability to implement its long-range business plan for various applications of its technology; the company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary US regulatory clearances applicable to applications of the company' technology; and management of growth and other risked and uncertainties that may be detailed from time to time in the company's reports filed with the Securities and Exchange Commission. This disclosure is intended to satisfy: SEC Section 6, 6.01 Regulation FD, disclosure and Section 7 and 7.0 as well as all applicable and presently effective Sarbanes-Oxley disclosure requirements under Regulation G. SOURCE: Mediscience Technology Corp. Mediscience Technology Corp. Michael Engelhart, 201-818-0050 mengelhart@mediscience.com or Peter Katevatis, 215-485-0362 metpk@aol.com MEDISCIENCE TECHNOLOGY CORP. SETS MEETING DATE WITH FDA TO REVIEW PRE-IDE SUBMISSION REGARDING CANCER DETECTION DEVICE; MEDISCIENCE TO MEET WITH FDA ON AUGUST 18, 2005 TO DISCUSS ITS CD-RATIOMETER DEV CHERRY HILL, N.J. July 26, 2005 Mediscience Technology Corp. (OTC:MDSC) announced that its wholly owned New York subsidiary, Medi-Photonics Development LLC, has been granted a date for a formal meeting with the FDA to discuss the possible commencement of a pivotal study by the FDA of its optical biopsy device, the CD-Ratiometer. The proposed indication for the use of the CD-Ratiometer is as a device that serves as an adjunct to diagnosis for cancer detection of the cervix and for other abnormalities.
The meeting is expected to expand upon the submission of the Pre-IDE document that was compiled by Schiff & Company, a firm specializing in international regulatory affairs, compliance and clinical research. Management expects to discuss aspects relating to clinical trials, fiber-optic probe details and the proposed indication of use of the CD-Ratiometer. "The meeting with the FDA on August 18th will address the factors that can put Mediscience on the path to obtaining a submission for the IDE (Investigational Device Exemptions). We are eagerly looking forward to the in person opportunity to discuss the clinical protocol and determine the clearest path towards clinical efficacy for the CD-Ratiometer," said President and Chief Operating Officer, Michael Engelhart. About Mediscience Technology: Mediscience Technology Corporation is engaged in the design, development and commercialization of medical devices that detect cancer and physiological change using frequencies of light that are emitted, scattered and absorbed to distinguish malignant, precancerous, or benign tissues from normal tissues. Mediscience's exclusive protected noninvasive technology combines the advantages of real-time results with enhanced diagnostic sensitivity and specificity compared with other methods of cancer detection. For additional information please visit: www.medisciencetech.com Investor Notice: Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the parties/company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include among other things, the availability of financing, the parties/company's ability to implement its long-range business plan for the joint or independent development of various applications of its technology/IP; the company's ability to enter into future agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary US regulatory i.e. FDA clearances applicable to applications of the company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the parties/company's reports filed with the Securities and Exchange Commission. This disclosure is intended to satisfy: SEC Section 6, 6.01 Regulation FD, disclosure and Section 7 and 7.0 as well as all applicable and presently effective Sarbanes-Oxley disclosure requirements under Regulation G. Contact: Contact Information: Mediscience Technology Michael Engelhart, President 201-925-5077 Peter Katevatis, CEO 215-485-0362 METPK@aol.com or Media: Investor Relations Group Janet Vasquez / Mary Ann Mullady, 212-825-3210 or Investor Relations: Investor Relations Group Erik Lux/Adam Holdsworth/John Nesbett, 212-825-3210 MEDISCIENCE TECHNOLOGY CORP. ANNOUNCES PRE-IDE MEETING REQUEST FOR CD-RATIOMETER, A CANCER DETECTION DEVICE CHERRY HILL, N.J. May 12, 2005 Mediscience Technology Corp. (OTC:MDSC) announces that its wholly owned New York subsidiary, Medi-Photonics Development LLC, has requested a formal meeting with the FDA to discuss the CD-Ratiometer, an optical biopsy device as an adjunct to diagnosis for cancer detection of the cervix and other abnormalities. The submission of the Pre-IDE document was made by Schiff &Company, a firm specializing in International Regulatory Affairs, Compliance and Clinical Research. "The meeting with the FDA has a purpose of determining any additional information required for submission of the IDE (Investigational Device Exemptions) and to determine the acceptability of the clinical protocol and establish the initial clinical efficacy of the CD-Ratiometer," said President and Chief Operating Officer, Michael Engelhart. How Our Technology Works Carcinogenesis is accompanied by molecular and structural changes in tissue. These changes affect the absorption, scattering and fluorescence properties of the tissue, and hence provide a method to spectroscopically (A spectroscope is a device that lets us find out what things are made of. It works by taking light and splitting it up into its component colors) distinguish malignant and pre-malignant tissue for normal or benign tissue. About Mediscience Technology Mediscience Technology Corporation is engaged in the design, development and commercialization of medical devices that detect cancer and physiological change using frequencies of light that are emitted, scattered and absorbed to distinguish malignant, precancerous, or benign tissues from normal tissues. Mediscience's exclusive protected noninvasive technology combines the advantages of real-time results with enhanced diagnostic sensitivity and specificity compared with other methods of cancer detection. Investor Notice: Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the parties/company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include among other things, the availability of financing, the parties/company's ability to implement its long-range business plan for the joint or independent development of various applications of its technology/IP; the company's ability to enter into future agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary US regulatory i.e. FDA clearances applicable to applications of the company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the parties/company's reports filed with the Securities and Exchange Commission. This disclosure is intended to satisfy: SEC Section 6, 6.01 Regulation FD, disclosure and Section 7 and 7.0 as well as all applicable and presently effective Sarbanes-Oxley disclosure requirements under Regulation G.
MEDISCIENCE TECHNOLOGY CORP. DEVELOPING CANCER DETECTION INSTRUMENT FOR ANALYZING SURGICAL BREAST TISSUE SPECIMENS AT POINT-OF-CARE Mediscience Technology, Corp. (OTCBB:MDSC) announced that it is in development of an adjunctive instrument called the Cancer Detection (CD) Map, to facilitate the acquisition of fluorescence images from surgical breast specimens (ex vivo) following lumpectomies and surgical procedures. The instrument will be used to define the margins of tumors at the point-of-care, thus allowing the physician to obtain greater success in achieving clear margins in real time during cancer surgery without the use of extrinsic dyes, drugs or other invasive agents. The CD-Map is highly sensitive and can acquire images in less than one second. Zoom capability allows the CD-Map to acquire images over an area that can vary from sub-cm to several cm with a resolution better than 100 mm. "We have performed prior studies on ex vivo tissue specimens and have demonstrated that fluorescence images acquired with the CD-Map can define regions of cancer, as well as identify other structures (i.e. veins, glands) inside tissue," said Michael Engelhart President and Chief Operating Officer. "We believe the CD-Map has the potential to greatly enhance patient outcomes at point-of-care through the delivery of clear margins confirmed through a pathology report," he added. The CD-Map is a UV/visible fluorescence imaging system designed to gain image emission from native fluorophors in tissue. A tunable light source and movable filters permit the acquisition of images at multiple combinations of emission and excitation wavelengths. Intensity ratio maps are computer generated from the fluorescence images and either the intensity images or pseudo-color ratio images are displayed. About Mediscience Technology Mediscience Technology Corporation is engaged in the design, development and commercialization of medical devices that detect cancer and physiological change using frequencies of light that are emitted, scattered and absorbed to distinguish malignant, precancerous, or benign tissues from normal tissues. Mediscience's exclusive protected noninvasive technology combines the advantages of real-time results with enhanced diagnostic sensitivity and specificity compared with other methods of cancer detection. Investor Notice Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the parties/company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include among other things, the availability of financing, the parties/company's ability to implement its long-range business plan for the joint or independent development of various applications of its technology/IP; the company's ability to enter into future agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary US regulatory i.e. FDA clearances applicable to applications of the company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the parties/company's reports filed with the Securities and Exchange Commission. This disclosure is intended to satisfy: SEC Section 6, 6.01 Regulation FD, disclosure and Section 7 and 7.0 as well as all applicable and presently effective Sarbanes-Oxley disclosure requirements under Regulation G. SOURCE: Mediscience Technology Mediscience Technology Michael Engelhart, 201-818-0050 Mengelhart@MediScience.com or Media: Investor Relations Group Janet Vasquez/ Lynn Granito, 212-825-3210 or Investor Relations: Investor Relations Group Erik Lux/Adam Holdsworth/John Nesbett, 212-825-3210 MEDISCIENCE TECHNOLOGY CORP. NAMES DR. JULIAN KIM AS CONSULTANT FOR THE DEVELOPMENT OF THE JOINTLY PROPOSED MICRO-ENDOSCOPIC DEVICE UTILIZING MTC PROPRIETARY TECHNOLOGY FOR NATIVE FLUORESCENCE MOLECULAR MEASUREMENTS OF BREAST DUCTS CHERRY HILL, N.J. Jan 27, 2005 Mediscience Technology, Corp. (OTCBB: MDSC) announced today that Dr. Julian Kim of the Cleveland Clinic has joined the company as a consultant. Dr. Kim is a Surgical Oncologist within the CC Dept. of General Surgery and a recognized expert in the study of applications of new technologies to assess breast ductal tissue. As a consultant to Mediscience, Dr. Kim will advise its management team on matters pertaining to: "guidance and expertise into the development of the jointly proposed micro-endoscopic device - Phase I project utilizing MTC proprietary technology for native fluorescence molecular measurements of breast ducts. Seminal product development work will occur at CUNY with government regulatory approval applications to follow. Dr. Julian Kim has performed extensive studies on the use of micro-endoscopic instrumentation to perform visual assessment of the human breast ductal system. He has published several peer-reviewed manuscripts and is a leading authority on the advantages and current limitations of mammary ductoscopy. He has a special interest in methods of improving the identification of abnormal cells lining the breast ducts during the ductoscopy procedure in women with high-risk or known diagnosis of breast cancer. Quote-"It is a great privilege to collaborate with Mediscience management and Dr. Robert Alfano at CUNY to determine whether the use of auto-fluorescence during mammary ductoscopy can help to identify areas of abnormality which should undergo biopsy. The Mediscience proprietary auto-fluorescent technology has the potential to markedly improve the diagnostic sensitivity and specificity of the mammary ductoscopy procedure and result in measurable improvements in patient care". Michael Engelhart Pres.COO "we continue to take advantage of our Intellectual Property in advancing the commercialization of screening and diagnostic cancer devices. We are delighted to have Dr Julian Kim of the Cleveland Clinic as a collaborator in our project --an individual who has demonstrated an expertise in detecting cancers of the breast in early stages. About Mediscience Technology Mediscience Technology Corporation and its New York subsidiary, Medi-photonics Development Company LLC, is engaged in the design, development and commercialization of medical devices that detect cancer and physiological change using frequencies of light that are emitted, scattered and absorbed to distinguish malignant, precancerous, or benign tissues from normal tissues. Mediscience's exclusive protected noninvasive technology combines the advantages of real-time results with enhanced diagnostic sensitivity and specificity compared with other methods of cancer detection. Investor Notice Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the parties/company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include among other things, the availability of financing, the parties/ company's ability to implement its long-range business plan for the joint or independent development of various applications of its technology/ IP; the company's ability to enter into future agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary US regulatory i.e. FDA clearances applicable to applications of the company's technology; and management of growth and other risked and uncertainties that may be detailed from time to time in the parties/company's reports filed with the Securities and Exchange Commission. This disclosure is intended to satisfy: SEC Section 6, 6.01 Regulation FD, disclosure and Section 7 and 7.0 as well as all applicable and presently effective Sarbanes-Oxley disclosure requirements under Regulation G. Reference www.infotonics.org/ResearchProjects/CompactPhotonicExplorers.asp Mediscience SB-2 registration filing dated Dec. 23, 2004 effective Jan 12, 2005 New England Journal of Medicine July-29-2004 (capsule endoscopic technology) CITIGROUP/Smith Barney Analyst Report 10-1-2004 see Pg. 20 (MTC/Infotonics)
THE FDA QUALIFIED THE MEDISCIENCE TECHNOLOGY CORP. FOR BOTH REDUCED OR WAIVED FDA FEES FOR ITS 2004 MEDICAL DEVICE 510K MARKET APPROVAL SUBMISSIONS CHERRY HILL, N.J., (Dec 17, 2003) - Mediscience Technology Corp. (MTC), (OTCBB:MDSC) of Cherry Hill, New Jersey, a developer of imaging technology for molecular detection of cancer and physiological change, announced: on December 11, 2003 the FDA, after review, qualified the Company under MDUFMA (The Medical Device User Fee and Modernization Act of 2002) allowing both reduced or waived FDA fees for its 2004 medical device 510K market approval submissions." and Company participation in expedited FDA review through FDA clinical inspections conducted independently by third party FDA approved "accredited" persons, directly employed by Mediscience. President and Chief Operating Officer Michael Engelhart stated, "we are making steady progress in all aspects of our business and continue to expand our leadership in the Optical Biopsy field." INVESTOR NOTICE: MEDISCIENCE TECHNOLOGY CORP. OTC-MDSC SECURES EXCLUSIVE WORLD-WIDE LICENSE TO US MOLECULAR IMAGING PATENT APPLICATIONS, EXPECTED TO EXTEND CORE TECHNOLOGY ADDITIONAL 17+ YEARS CHERRY HILL, N.J., (Dec 3, 2003) - Mediscience Technology Corp. (MTC), (OTCBB:MDSC) of Cherry Hill, New Jersey, a developer of imaging technology for molecular detection of cancer and physiological change, announced its contractual acquisition of two exclusive world-wide licenses for US patent applications filed by The Research Foundation City University of New York (RFCUNY). 1. 'Stokes-Shift Fluorescence spectroscopy for detection of disease and physiological state of specimen'and 2. 'Three-dimensional Radiative Transfer Tomography for Turbid Media.'The work results from the Company's continual 10-year+ University research funding relationship. President and Chief Operating Officer Michael Engelhart and CUNY inventor Dr. Robert Alfano state that 'the patents, when issued, would extend the Company's core technology in Optical Biopsy for an additional 17+ years, thus expanding, maintaining and continuing our IP leadership in the Optical Biopsy field.' NOTE: SEE: Mediscience SEC 8-k filing dated: December 3, 2003 Web Page: MEDISCIENCETECH.com See (IEEE Journal of selected topics in Quantum Electronics March-April 2003 Vol. 9 Dr. Alfano page 148 and page 189.) INVESTOR NOTICE: Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include among other things, the availability of financing, the company's ability to implement its long-range business plan for various applications of its technology; the company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary US regulatory clearances applicable to applications of the company'technology; and management of growth and other risked and uncertainties that may be detailed from time to time in the company's reports filed with the Securities and Exchange Commission. This disclosure is intended to satisfy: SEC Section 6, 6.01 Regulation FD, disclosure and Section 7 and 7.0 as well as all applicable and presently effective Sarbanes-Oxley disclosure requirements under Regulation G. SOURCE: Mediscience Technology Corp. Mediscience Technology Corp., Cherry Hill Michael Engelhart, mengelhart@thmgroup.com or Peter Katevatis Esq. metpk@aol.com BREAKTHROUGH IN DETECTING CANCEROUS TISSUE VIA STOKES SHIFT EMISSION SPECTROSCOPY (Nov. 24, 2003) A research team at City College's Institute for Ultrafast Spectroscopy and Lasers (IUSL) headed by Dr. Robert R. Alfano has announced development of a new technique that is much more sensitive than conventional fluorescence Spectroscopy to detect cancerous bio-molecules and structures. Called "Stokes Shift Emission Spectroscopy," the method grows out of seminal work done at the IUSL for the past two decades. In 1984. IUSL researchers first demonstrated that light could be used to detect cancer from key molecules without removing tissue. According to Dr. Alfano, "this revolutionary breakthrough will make optical biopsy the new medical frontier for cancer diagnosis and other medical applications." The emission and absorption of organic molecules in different hosts has been investigated for over fifty years. Information on molecules in different states of matter has been obtained by measuring emission and absorption spectra. For over four decades spectroscopy has played an important role in understanding the fundamental processes that occur in biology, chemistry and solid-slate physics. Since the discoveries at the IUSL in 1984, spectroscopy has been investigated as a tool to separate cancer, benign and surrounding tissue regions. Typically, tissue is excited at a given wavelength to emit radiation at different wavelengths, which are then used to characterize the tissue. The emission wavelengths serve as "spectral fingerprints" for changes in the structure and content of various proteins in the tissue. "For organic molecules, typically, the peaks of absorption and emission occur at different wavelengths," Dr. Alfano said, "and the emission band occurs at lower energy than the excitation band." This difference between the emission and absorption peaks, known as the Stokes Shift, depends in part on the polarity of the host environment surrounding the emitting organic molecule. The new detection method developed at the IUSL combines the fluorescence and absorption spectra of molecules in tissue and is known as "Stokes Shift Emission Spectroscopy." "The excitation and emission wavelengths are scanned simultaneously with a fixed value between the excitation and emission wavelengths," according to Dr. Alfano. "This approach is much more sensitive than ordinary fluorescence spectroscopy and has delivered dramatically improved results in detecting changes in native bio-molecules. It offers great promise, therefore, in detecting cancerous, pre-cancerous and normal tissues." When comparing the effectiveness of the Stokes Shift Emission Spectroscopy (SS) method with conventional fluorescence spectroscopy it is clear that this method is a more selective and a more effective means of distinguishing cancerous from normal tissue. Dr. Alfano called this as a "giant step forward for scientists at the IUSL," who pioneered using optical spectroscopy to diagnose cancer without removing tissue. The latest advance has the potential to detect tumors involving the breast, cervix, gastrointestinal tract, head and neck, prostate, liver, brain, kidney, bladder and other organs. This work has been supported, in part, by Mediscience Technology Corp. and funds from organized research at The City University of New York. CCNY RECEIVES $6 MILLION NASA GRANT TO ENHANCE PHOTONICS RESEARCH With support from a five-year $6 million University Research Center Program grant from the National Aeronautics and Space Administration (NASA), City College has established a Center for Optical Sensing and Imaging (COSI) designed to provide benefits in the technical, scientific and social fields. The Center’s primary goal is to develop improved sensing and imaging instruments and techniques that will contribute to NASA research and future NASA missions. It will also attract and train underrepresented minority students in related science and engineering disciplines. COSI is headed by the renowned Dr. Robert R. Alfano, Distinguished Professor of Science and Engineering at CCNY, and Dr. Sam Ahmed, Herbert G. Kayser Professor of Electrical Engineering. “The high quality research, economic and social impacts that this program will produce will be of significant value to the people of New York State and could aid in the recovery of New York City,” said Dr. Alfano, who is also heads CCNY’s Institute for Ultrafast Spectroscopy and Lasers, and directs New York State’s CUNY Center for Advanced Technology in Ultrafast Photonics and Applications. Dr. Alfano said COSI promises many tangible benefits, including increased educational opportunities for minority students; a better-trained technical workforce; discoveries that improve lives; and commercial innovations to help local businesses improve efficiency and stay competitive. The new Center will enable CCNY to expand its efforts in training and graduating minority US students in the sciences and engineering by establishing a strong research, education and outreach program to recruit, retain, mentor and train students. CCNY is an important Other Minority University (OMU) and Hispanic Serving Institution (HSI) with a strong record of training and educating talented students from underrepresented ethnic groups for careers in the sciences and engineering. “The program will train a minimum of 16 graduate and 10 under-graduate students annually, and will also institute a vigorous K-12 science education program,” said Dr. Manuel Zevallos, COSI’s Administrative and Technical Coordinator. The scientific and technological objectives of COSI include development of optical techniques and instruments (for both in-situ and ground- and satellite-based remote applications) for:
The Center brings together the teams of two major existing NASA institutional programs at City College: NASA IRA (Tunable Solid State Lasers) of the Institute for Ultrafast Spectroscopy and Lasers (IUSL), and NASA PAIR (Remote Sensing and Environmental/Climat Studies) of the International Center for Environmental Resources and Development (ICERD), to form a complementary multi-disciplinary University Research Center. CCNY also is home to the New York State Center for Advanced Technology in Ultrafast Photonics and the NOAA Cooperative Center for Remote Sensing Science and Technology. Other CCNY researchers participating in the Center include Dr. Swapan Gayen, Dr. Vladimir Petricevic, Dr. Alvin Katz, Dr. Wubao Wang, Dr. Mikhail Sharonov and Dr. Shengkun Zhang (Physics); Dr. Barry Gross, Dr. Fred Moshary and Dr. Ping-Pei Ho (Electrical Engineering); Dr. Jeffrey Steiner (Earth and Atmospheric Sciences), and Dr. Reza Khanbilvardi (Civil Engineering). Dr. Charles B. Watkins, Herbert G. Kayser Professor of Mechanical Engineering, is COSI’s Educational and Outreach Coordinator. The CCNY researchers will maintain their close collaboration with NASA scientists and engineers, as well as with partners from industry such as Lockheed Martin, Raytheon, and GER Inc. to keep the research focused on NASA and real-world needs, and to facilitate transfer of dual use technology to the marketplace. Dr. Alfano said that COSI would enjoy strong support from CCNY and the City University of New York (CUNY) and was a welcome new component to strengthen CUNY’s Photonics Initiative. MEDISCIENCE TECHNOLOGY ANNOUNCES FORMATION OF NEW SUBSIDIARY TO DEVELOP POTENTIAL CLINICAL APPLICATION FOR NON-INVASIVELY DIAGNOSIS OF PROSTATE CANCERS. Cherry Hill, NJ (June 4, 2003) - Mediscience Technology (OTCBB - "MDSC"), a medical diagnostics device company, is pleased to announce the formation of "PROSCREEN, LLC". The Company, a wholly owned subsidiary of Mediscience Technology has a potential clinical application for non-invasively diagnosing prostate cancers without removing prostate tissues. Prostate cancer has a high incidence and mortality rate for men. Every year, nearly 180,000 new prostate cancer cases are diagnosed, and about 37,000 deaths annually are caused by prostate cancers in U.S. Current techniques for detection of prostate cancers have limited accuracy. The regular methods for monitoring prostate cancers are the prostate specific antigen (PSA) blood test and a digital rectal examination (DRE). When the PSA level is elevated or the DRE abnormal, there is a one-in-three chance that cancer is present. This can only be confirmed by a needle biopsy of the prostate. In the biopsy, a number of cores of prostate tissue are taken with a thin needle guided into selected regions of the prostate with an ultrasound probe. Since the ultrasound imaging has poor spatial resolution and contrast, and needle biopsy is invasive, better methods are needed to develop high resolution and noninvasive techniques to detect early small prostate cancers. Michael Engelhart, President and COO of Mediscience Technology said, "The prospects for this project are very exciting and can potentially enhance prostate diagnosis and thereby create more favorable patient outcomes. We are evaluating various methods to determine the best imaging technique. After we select the best approach, we will develop a prototype spectral polarization imaging unit with an optical fiber probe for prostate cancer detection, and engage in performing clinical tests." Engelhart added, "Our initial project will include three phases. In phase 1, we will complete the evaluation of the imaging technique to select the best imaging method for the device design. In phase 2, we will design the device, purchase the parts, and build a prototype spectral polarization imaging unit with an optical fiber probe. In phase 3, we will assist in performing clinical test with a medical collaborator such as Hackensack University Medical Center and modify the unit based on the clinical results." Peter Katevatis, Chairman/CEO "The formation of "PROSCREEN, LLC" is consistent with Mediscience's overall strategy of rolling out the company's constellation model; the first of which was Photonics for Women's Oncology, LLC." We continue to build our IP and exiting product base directly from our on-going research relationship at CUNY's INSTITUTE FOR LASERS AND ULTRA-FAST SPECTROSCOPY with the dedication of its Director, Dr. Robert Alfano, and other associated medical and engineering staff. About Mediscience Technology---Mediscience Technology Corp. is engaged in the design and development of diagnostic medical devices that detect cancer using light induced native tissue fluorescence spectroscopy to distinguish between malignant normal, dysplastic or benign tissue. This press release contains forward-looking statements involving risks and uncertainties that may cause actual results to differ materially from those indicated due to a number of factors. The Company's plans and objectives are based on assumptions involving judgments with respect to future economic, competitive, and regulatory and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the control of the Company. Therefore, there can be no assurance that the forward-looking statement will prove to be accurate. The Company's documents filed with the SEC identify important factors that may cause the actual results to differ materially from those indicated by the forward-looking statements. This disclosure is intended to satisfy: SEC Section 6, 6.01 Regulation FD, disclosure and Section 7 and 7.0 as well as all applicable and presently effective Sarbanes-Oxley disclosure requirements under Regulation G. Reference:
MEDISCIENCE TECHNOLOGY APPOINTS MICHAEL ENGELHART PRESIDENT AND CHIEF OPERATING OFFICER EFFECTIVE IMMEDIATELY. Cherry Hill, NJ (April 28, 2003) - Mediscience Technology (OTCBB - "MDSC"), a medical diagnostics device company, is pleased to announce that effective April 26, 2003, Michael Engelhart has been appointed President and Chief Operating Officer Mr. Engelhart, 40, focus will be to evaluate and create alternative strategies in an effort too maximize shareholder value and create the needed funding mechanism. Effective April 26, 2003 Mr. Sidney Braginsky, former President COO and the Registrant agreed to the termination of his July 9, 2001 agreement effective retroactively as of July 9, 2001. He will continue as a Board member providing consulting services to the Board and President COO Michael Engelhart as needed. "We are pleased to welcome someone with Michael's operational experience. Mediscience continued progress will require a continued focus on operational excellence as well as successful corporate development activities. Michael brings a fresh perspective and a wealth of experience in ensuring that we make the best use of our capital," said Peter Katevatis, Esq., Chairman and CEO. "I appreciate the opportunity presented and confidence of the Mediscience Board of Directors and Peter Katevatis, Chairman and CEO in what could be a very important set of commercial ventures aimed at early cancer detection. We are pleased with the pace of our continued development of the cervical cancer detection device, where we have completed a final prototype. We are encouraged by the early results of our capital raising and business development activities that support and expedite the path to commercialization." Said Michael Engelhart, President and COO of Mediscience. About Mediscience Technology---Mediscience Technology Corp. is engaged in the design and development of diagnostic medical devices that detect cancer using light induced native tissue fluorescence spectroscopy to distinguish between malignant normal, dysplastic or benign tissue. This press release contains forward-looking statements involving risks and uncertainties that may cause actual results to differ materially from those indicated due to a number of factors. The Company's plans and objectives are based on assumptions involving judgments with respect to future economic, competitive, and regulatory and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the control of the Company. Therefore, there can be no assurance that the forward-looking statement will prove to be accurate. The Company's documents filed with the SEC identify important factors that may cause the actual results to differ materially from those indicated by the forward-looking statements. This disclosure is intended to satisfy: SEC Section 6, 6.01 Regulation FD, disclosure and Section 7 and 7.0 as well as all applicable and presently effective Sarbanes-Oxley disclosure requirements under Regulation G. Reference 8-K EDGAR filing April 28,2003/ Company's website at www.medisciencetech.com/forms/8-K_4_29_03.htm Contact Persons: Pres. COO Michael Engelhart (201) 818 0050 mengelhart@thmgroup.com : Mediscience Technology Corp. Peter Katevatis Esq. Chairman/CEO (856) 428 7952 metpk@aol.com. MEDISCIENCE TECHNOLOGY APPOINTS MICHAEL ENGELHART TO THE BOARD OF DIRECTORS Cherry Hill, NJ (March 14, 2003) - Mediscience Technology (OTCBB - "MDSC"), a medical diagnostics device company, is pleased to announce that effective March 13, 2003 Michael Engelhart has been appointed to the Board of Directors. Mr. Engelhart, 40, is the CEO of THM Group, LLC, a New Jersey based strategic consulting organization. THM Group was retained by Mediscience to evaluate and create alternative strategies in an effort too maximize shareholder value. "We are pleased to add to our board someone with Michael's operational experience in running strategic and corporate development functions at both large and small diversified companies. Mediscience continued progress will require a continued focus on operational excellence as well as successful corporate development activities. Michael will bring a fresh perspective and a wealth of experience in ensuring that we make the best use of our capital," said Peter Katevatis, Esq., Chairman and CEO of Mediscience. About Mediscience Technology Mediscience Technology Corp. is engaged in the design and development of diagnostic medical devices that detect cancer using light induced native tissue fluorescence spectroscopy to distinguish between malignant and normal or benign tissue This press release contains forward-looking statements involving risks and uncertainties that may cause actual results to differ materially from those indicated due to a number of factors. The Company's plans and objectives are based on assumptions involving judgments with respect to future economic, competitive, and regulatory and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the control of the Company. Therefore, there can be no assurance that the forward-looking statement will prove to be accurate. The Company's documents filed with the SEC identify important factors that may cause the actual results to differ materially from those indicated by the forward-looking statements. Contact Persons: THMGROUP LLC Michael Engelhart (201) 818 0050 mengelhart@thmgroup.com: Mediscience Technology Corp. Peter Katevatis Esq. Chairman/CEO (856) 428 7952 metpk@aol.com For more information, visit the Company's website at www.medisciencetech.com. MEDISCIENCE TECHNOLOGY SELECTS THM GROUP FOR COMMERCIALIZATION PHASE OF CANCER DETECTION TECHNOLOGY For Immediate Release Cherry Hill, NJ (January 22, 2003) - Mediscience Technology (OTCBB - "MDSC") of Cherry Hill, New Jersey, a company developing technology for molecular detection of cancer and physiological change, announced the appointment of THM Group, LLC as exclusive advisor to explore options for the company to commercialize its technology. Peter Katevatis Esq., Chairman said" Mediscience has steadfastly developed its science to the conclusion of the research phase and now with the expert participation and assistance of THM Group expects to timely commercialize its paradigm platform technology. Michael Engelhart, Chief Executive Officer of THM Group said, "We are looking forward to putting all of THM's capabilities behind the patent platform and prototype equipment of these exciting devices that we believe will significantly improve upon early cancer detection. We are pleased that Mediscience has entrusted us to provide options in an effort to maximize the return on their investment." About Mediscience Technology Mediscience Technology Corp. is engaged in the design and development of diagnostic medical devices that detect cancer- using light induced native tissue fluorescence spectroscopy to distinguish between malignant and normal or benign tissue.
About THM Group THM Group is focused on raising capital, carrying out project feasibility and business development projects for going businesses of private and public companies, and acting as an officer in early stage or troubled companies This press release contains forward-looking statements involving risks and uncertainties that may cause actual results to differ materially from those indicated due to a number of factors. The Company's plans and objectives are based on assumptions involving judgments with respect to future economic, competitive, and regulatory and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the control of the Company. Therefore, there can be no assurance that the forward-looking statement will prove to be accurate. The Company's documents filed with the SEC identify important factors that may cause the actual results to differ materially from those indicated by the forward-looking statements. Contact Persons: THMGROUP LLC Michael Engelhart (201) 818 0050 mengelhart@thmgroup.com: Mediscience Technology Corp. Peter Katevatis Esq. Chairman/CEO (856) 428 7952 metpk@aol.com SEC 8-k filed 1/22,2003, and posted on Company web medisciencetech.com per Sarbanes-Oxley Full Disclosure requirements THE RESEARCH FOUNDATION CITY UNIVERSITY OF NEW YORK (RFCUNY) ACQUIRES MAJOR EQUITY POSITION IN MEDISCIENCE TECHNOLOGY CORP. Cherry Hill, NJ (June 30, 2002) - Mediscience Technology Corp. (MTC), (OTCBB- "MDSC") of Cherry Hill New Jersey, a developer of imaging technology for molecular detection of cancer and physiological change, announced its revised contract with The Research Foundation City University of New York (RFCUNY) effective May 31, 2002 The agreement, erases all (MTC) debt, reduces all company royalty rate obligations from 5% to 3.25% and affirms ownership and/or exclusive license of all Medical Applications embodied in (MTC's) patent list, in exchange for consideration to (RFCUNY) of:
(RFCUNY) now has a total 4% beneficial interest in Mediscience common Rule 144 shares, exercisable as Share Warrants at one dollar ($1.00) per share for a total of One Million one hundred thousand (1,100,000) shares. Effective May 31, 2002 (MTC) fully funded its new agreement-- Term: July 1, 2002 to June 30, 2003, with "The Institute for Ultra fast Spectroscopy and Lasers Center for Ultrafast Photonics and Mediphotonics Laboratory of City University of New York". This 10-year+ relationship provides continual technical and research assistance to in support of existing and anticipated clinical trials in the United States and India. NOTE: SEE: Mediscience SEC/EDGAR 8-k filing 6/1/2002
Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include among other things, the availability of financing, the company's ability to implement its long-range business plan for various applications of its technology; the company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the company' technology; and management of growth and other risked and uncertainties that may be detailed from time to time in the company's reports filed with the Securities and Exchange Commission. MEDISCIENCE TECHNOLOGY SELECTS MR. SIDNEY BRAGINSKY AS NEW PRESIDENT AND COO Cherry Hill, NJ -- July 12, 2001 (SEC-EDGAR filing 10-QSB)-- Effective July 9th 2001 Peter Katevatis, Esq. Chairman CEO on behalf of the Company entered into an employment relationship with Mr. Sidney Braginsky as the new President and COO. Mr. Braginsky was formerly with OLYMPUS OPTICAL LTD for 27 years most recently as President CEO of OLYMPUS AMERICA, Inc., the Olympus US subsidiary. OLYMPUS LTD. is a multinational corporation headquartered in Tokyo Japan and a world leader in microscopes, endoscopes, automatic blood and fluid chemistry analyzers measuring research, industrial and consumer products. The Company will seek investment and/or corporate partners to support the funding of a joint effort between itself, Sarnoff Corporation, and the Mediphotonics Laboratory of the City University of New York to develop and commercialize an advanced, second generation version of its proprietary two-dimensional fluorescence imaging system for early cancer detection. Mr. Braginsky is a present board member of, NOVEN Pharmaceuticals, REDOX Pharmaceuticals, ELECTRO-OPTICAL SYSTEMS, Inc., ESTEK CARDIOLOGY, Chairman of Double D Venture Funds LLC and Chairman of the Board of City College of New York's Robert Chambers Laboratory. MEDISCIENCE CD-SCAN EFFECTIVE IN CORNELL/NEW YORK MEDICAL BARRETT'S ESOPHAGEAL RELUX STUDY IN DISTINGUISHING NORMAL ESOPHAGEAL TISSUE FROM BARRETT'S OR ADENOCARCINOMA Cherry Hill, N.J., March 24, 1999 Mediscience Technology Corp. (OTC Bulletin Board: MDSC), pioneer developer and designer of non- invasive photonic technology used in medical diagnostic instruments that detect cancer/molecular changes based upon differentiations in the amount of light re-emitted from malignant and benign tissue reports findings published January 23-29, 1999 at the SPIE Optical Tomography and Spectroscopy of Tissue lll Conference by Principle Investigator Paul M. Basuk MD, New York Hospital-Cornell Medical Center together with researchers Dr. Alvin Katz and Dr. Howard Savage from the New York State Center of AdvancedTechnology in Ultra Fast Photonics, (CUNY) in a Mediscience supported "Investigation of Barrett's esophagus by ultraviolet and visible fluorescence emission and excitation spectroscopy." (Optical Biopsy, Section-presentation talk No. 3597-61). Paul M. Basuk MD used the Mediscience CD-scan device on excised human gastrointestinal tissue to monitor patients with Barrett's esophagus, (a pre-malignant condition characterized by symptomatic gastroesophageal reflux), and concluded that "his work shows UV emission measurements can effectively distinguish normal esophageal tissue from Barrett's or adenocarcinoma. Further preliminary data also indicates that the combination of UV emission and excitation measurements can potentially separate non-dysplasia Barrett's from dysplasia and cancer as well as from normal tissues." On March 19, 1999 The New England Journal of Medicine Vol.340, No.11 reported on a study of "Symptomatic Gastrosophageal Reflux as a risk factor for esophageal Adinocarcinoma" concluding that there is a strong and probable causal relation between gastroesophageal reflux and esophageal adenocarcinoma. Esophageal adenocarcinoma is treatable but rarely curable, mortality is high and successful treatment depends on early detection. Mediscience optical detection of dysplasia, intergrated into an endoscopic examination, can significantly improve the accuracy of biopsy sight selection, thereby increasing the likelihood of early detection of malignancy, and reducing the number of random negative biopsies during an upper gastrointestinal tract endoscopic examination. Mediscience experience in excitation of important tissue molecules shows improved diagnostic accuracy in the range of 80 to 90% with measurement time a few seconds (real-time). The greatest increase in the incidence of this disease is seen in males, particularly over the age of 60, with the major risk factors of alcohol and tobacco. Since Barrett's esophagus appears to be a predisposing factor for cancer, screening such high risk patients for the development of adenocarcinoma would be appropriate. Mediscience propriety technology predictably can retro-fit existing and future endoscopes for this and other diagnostic purposes creating intelligent instrumentation for the physician - a significant world-wide market opportunity. Mediscience has been conducting research in this field since 1988 and presently is conducting two FDA approved studies. "Yale/Mediscience "in-vivo" Phase ll womens health related non-significant risk device was approved January 25, 1999" and FDA approved Phase ll "in-vivo" study for Oral Aerodigestive cancer, approved after successfully completed the Phase I study at Memorial Sloan Kettering New York City. Under the direction of Dr. Stimson Schantz with NCI support. The company intends to additionally file with the FDA in furtherance of Dr. Basuk's work. Both Dr. Basuk's and Dr. Schantz's work concern alcohol and tobacco related cancer. Mediscience owns exclusive rights to 17 patents in the field of Bio-Optics. Its CD-Scan and other prototype devices are based on its patented optical fluorescence. spectroscopy technology. With the current medical validation and concern regarding gastroesophageal reflux, there exists a major market opportunity in the United States for Mediscience Technology. In the far east (China, Japan, East and South Africa) the disease is almost epidemic, (130 cases per 100,000 population), indicating mass screening as essential for those and other communities. Certain matters discussed in this announcement contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934 that involve material risks to, and uncertainties in the company's business which may cause actual results to differ materially from those anticipated by the statements made herein.
FDA APPROVES PHASE II IN VIVO USE OF MEDISIENCE CD-SCAN OPTICAL SYSTEM AS NON-SIGNIFICANT RISK DEVICE IN YALE UNIVERSITY/MEDISCIENCE SIGNIFICANT WOMENS HEALTH STUDY. (March 8, 1999) CHERRY HILL, NJ, March 8, 1999 - Peter Katevatis announced that Mediscience Technology Corp. (OTC.MDSC), developer and designer of non-invasive photonic technology used in medical diagnostic instruments that detect cancer/molecular changes based upon differentiations in the amount of light re-emitted from malignant and benign tissue, has entered into are search agreement with Yale University under which Frederick Naftolin Chairman OBGYN Yale University Dept. of Obstetrics and gynecology as the principle Investigator, will investigate the biological basis of fluorescence as applied to medically significant OBGYN Health issues using the Mediscience CD-Scan with FDA approval (Jan. 25, 1999) as a non-significant risk device for the proposed in Vivo Phase II Clinical investigation. In particular, the autofluorescence from specific areas will be examined to establish non-invasive diagnostic information of value in specificity and analysis to the OBGYN practitioner. The FDA approved clinical trial will obtain in Vivo and statistics which will lead o a broader multi-site effort. Mediscience has been conducting research in this field since 1988 and in a separate effort successfully completed a FDA approved phase I clinical evaluation with CD-Scan in human Patients under an NCI supported study of Aerodigesrtive (tobacco related) Cancer at Memorial Sloan-Kettering Hospital, New York City and is presently positioned to enter FDA Approved Phase II and Phase II (multi-sites) towards pre-market approval under the continued direction of principle investigator Stimson Schantz MD. The potential annual market for clerical cancer and related woman health issues is approximately $1.25 Billion. Preliminary results of the Yale/Mediscience FDA approved in Vivo clinical trial are expected during 1999. Mediscience, a leader in this field, owns exclusive rights to 17 pioneering and early seminal patents in the field of Optical Biopsy and Optical Mammogrophy. iTS CD-Scan and other prototype devices are based on its patented optical fluorescence spectroscopy technology. Certain matters discussed in this announcement contain forward-looking statements within the meaning of section 27A of the Securities act of 1933 and Section 21E of the Securities Act of 1934 that involve material; risks to, and uncertainties in the company's business which may cause actual results to differ materially from those anticipated by the statement made herein. MEDISCIENCE US PATENT ISSUED: Techniques to detect cellular malignancy for PAP SMEAR type samples(June 3, 1997) CHERRY HILL, NJ, July 1 1997 - Peter Katevatis, President and CEO of Mediscience Technology Corp. (MDSC, OTC Bulletin Board), announced that MTC has acquired the rights to a new patent for a technique to detect cellular malignancy. This technique can be used to screen in vitro cell smears. Using the fundamental principle known as extrinsic fluorescence spectroscopy, it is possible to distinguish normal cells from malignant cells that have been treated with a fluorescent dye. The fluorescent dye is preferably absorbed by malignant cells resulting in an enhanced discrimination fluorescent signature compared to that from normal cells. The technique can he deployed in an automated system to map the distribution of malignant cells, such as found in Pap smear-type samples. The inventors of the patent (#5,635,402: June. 3, 1997) - Robert R. Alfano, Cheng. H. Liu, Wei L. She, and Yury Budanski -are associated with the Mediphotonics Laboratory and the Institute for ultrafast Spectroscopy and Lasers at City College of New York. Alfano and coworkers hold patents for many cancer diagnostic and imaging techniques. MediScience is a technology development corporation specializing in medical diagnostic applications that use lasers and optical imaging MTC is receptive to inquiries on licensing and joint ventures on this and other technologies it owns. Except for the historical information contained herein, the matters set forth in this news release arc forward-looking statements that are dependent on certain risks and uncertainties including such factors, among others, as the Company's ability to continuously satisfy the FDA's requirements for safety of its devices, its ability to raise sufficient capital to conduct the human clinical trials necessary to ultimately prove the safety of its devices and its ability to sell its devices to health care providers if it is successful in completing their development. MEDISCIENCE ANNOUNCES "INCUBATOR" SPACE ON CAMPUS Cherry Hill, New Jersey, (March 19, 1997). Mediscience Technology Corp. (OTC-MDSC) announced today that it has executed a lease agreement with City College of New York (CCNY) providing space in an "incubator" for transfer of the technology from Metiphotonocs Laboratory (MPL) at CCNY to MDSC. This lease is the first step in producing units. Prototypes of the Company's diagnostic instruments will be designed and assembled by MPL staff working in concert with personnel from an engineering design firm that has been retained by the company. These units will be used in clinical evaluation. Know-how will be transferred to the company for its manufacturing stages for well defined endoscopic based devices for the gastroenterology, gynecology and urology markets. The next phase for MDSC will be to create a pilot facility in which several diagnostic instruments will be assembled. The location of the incubator and pilot facility affords Mediscience the advantage of having its design engineers work side-by-side with the MPL research scientists and all within close proximity to the medical institutions in the New York are where the instruments are to be clinically tested. The Company plans to manufacture and assemble its medical device products on relationship with contract manufactures and/or business partners in the medical device field when the devices are commercialized. Contract manufacturer(s) will be selected from a list of highly qualified companies who are familiar with the regulatory requirements of the FDA for the manufacture of medical devices, who are registered with and in good standing with the FDA. Except for the historical information contained herein, the matters set forth in this news release are forward-looking statements that are independent in certain risks and uncertainties including such factors, among others, as the Company's ability to continuously satisfy the FDA's requirements for safety of its devices, its ability to sell its devices to health care providers if it is successful in completing their development. Mediscience owns exclusive rights to 15 patents in the field of Bio-Medical Optics. Its CD Scan and CD Ratiometer prototype medical devices are based on its patented optical fluorescence spectroscopy technology which can distinguish between normal and cancerous tissue in-vivo (in the body) in a non-invasive manner by optically scanning the surface of suspect tissue with a fiberoptic probe and comparing the resulting fluorescence spectral response to a similar scan of healthy tissue. MEDISCIENCE ANNOUNCES FDA "IDE" APPROVAL(Jan. 8, 1997) Cherry Hill, New Jersey. January 8, 1997 - Medisciencc Technology Corp. (OTC-MDSC) announced today that it received FDA approval of its Investigational Device Exemption to initiate phase II clinical trials with its CD Scan medical device for early stage detection of cancer. The specific protocol approved for study with this IDE is a double blind, randomized study of patients with oral leukoplakia. a pre-cancerous condition in the mouth. Half the patients will be treated with the drug; l3-cis retinoic acid and the other half with placebo and the entire study population will he followed up routinely during the study period with the CD Scan and via other techniques to assess changes of the patient's medical condition. The Company hopes to demonstrate that its CD Scan device and its Tissue Fluorescence technology can provide in vivo (in the body) results, non-invasively, comparable to those derviced from excisional biopsy. If successful in this trial, Mediscience contemplates expand-ing the study population to gather sufficient data to support premarket approval. This human clinical study will be conducted at the Sloan Kettering Cancer Research Center in New York City. The study co-sponsors are Mediscience and the National Cancer Institute. "The Company has made tremendous progress in the last year", according to Peter Katevatis, Chairman of Mediscience. "Approval of this IDE demonstrates that Mediscience has now developed the know-how and necessary infrastructure to deal effectively with the FDA on matters of importance both to the Company and the FDA." Mediscience is already preparing its next IDE submission which is targeted at a gastrointestinal tract pre-cancerous condition that will employ both the Company's CD Scan device and its second-generation device, CD Ratiometer. The Company hopes to be in a position to file for IDE approval to conduct that study later this quarter. In this planned clinical trial the Company's objective will be to demonstrate the technical and clinical feasibility of non-invasive detection of pre-cancerous conditions of the esophagus at an early enough stage where preventive therapy is highly effective before proceeding into the "pivotal" clin-ical trial to support premarket approval of its device for that application. Except for historical Information contained herein, the matters set forth in this news release are forward-looking statements that are dependent on certain risks and uncertainties including such factors, among others, as the Company's ability to continuously satisfy the FDA's requirements for safety of its devices. its ability to raise sufficient capital to conduct the human clinical trials necessary to ultimately prove the safety and effectiveness of its devices and its ability to sell its devices to health care providers if it is successful in completing their development. Mediscience owns exclusive rights to IS patents in the field of Bio-Medical Optics. Its CD Scan and CD Ratiometer medical devices alt based on its patented Tissue Fluorescence technology which can distinguish between normal and cancerous tissue in vivo (in the body) in a non-invasive manner by optically scanning the surface of suspect tissue with a fiberoptic probe and comparing the resulting fluorescence spectrum to a similar scan of healthy tissue. MEDISCIENCE TECHNOLOGY CORP. ANNOUNCES COMPLETION OF DEVELOPMENT OF ITS OPTICAL BIOPSY CANCER DIAGNOSTIC RATIOMETER AND SUBMISSION TO THE FDA OF THE PRE-IDE BRIEFING MATERIALS CHERRY HILL, N.J.--(BUSINESS WIRE)--Dec. 9, 2004-- Mediscience Technology Corp. (OTC:MDSC) announced today that its wholly owned New York subsidiary, Medi-Photonics Development LLC, has completed development of its Optical Biopsy Cancer Diagnostic Ratiometer(TM) for the molecular screening and detection of cancer and physiological change. The Company also announced that it had submitted its Pre-IDE briefing materials to the United States Food and Drug Administration (FDA). President and Chief Operating Officer Michael Engelhart stated "The timely completion of our Optical Biopsy Cancer Diagnostic Ratiometer should provide us with a clear path for our applications platform commercialization in the early screening, detecting and diagnosing of cancers of the cervix, mouth, esophagus and gastro intestinal tract." Engelhart added "We have submitted our initial Pre-IDE briefing materials for early screening and detection of abnormalities including cancer of the cervix with the FDA for marketing in the U.S." Safe Harbor Statement: To the extent that any statements made in this press release contain information that is not historical, these statements are essentially forward-looking. Forward-looking statements can be identified by the use of words such as "expects," "plans," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, among others, the availability of financing, the Company's ability to implement its long-range business plan for various applications of its technology, the Company's ability to enter into agreements with any necessary marketing and/or distribution partners, the impact of competition, the obtaining and maintenance of any necessary US regulatory clearances applicable to applications of the Company' technology, and management of growth and other risks and uncertainties that may be detailed from time to time in the Company's reports filed with the Securities and Exchange Commission. SEE: Web Page: medisciencetech.com Mediscience Form 8-K dated December 9, 2004 SOURCE: Mediscience Technology Corp.
MEDISCIENCE TECHNOLOGY CORP./MEDI-PHOTONICS DEVELOPMENT COMPANY LLC AND INFOTONICS TECHNOLOGY CENTER ANNOUNCE THEIR DEFINITIVE COLLABORATIVE R&D EQUITY AGREEMENT ( BW)(NJ-MEDI-PHOTONICS)(MDSC) Mediscience Technology Corp./Medi-photonics Development Company LLC and Infotonics Technology Center Announce Their Definitive Collaborative R&D Equity Agreement. CHERRY HILL, N.J.--(BUSINESS WIRE)--Nov. 10, 2004--Infotonics Technology, a Consortium of Corning, Inc.,Eastman Kodak Co. and Xerox Corp., to Develop the Mediscience (CPE) "Compact Photonic Explorer" Pill Camera. Medi-photonics Development Company LLC, the NY subsidiary of Cherry Hill New Jersey-based Mediscience Technology Corp. (MTC), (OTCBB:MDSC), a developer of proprietary non-invasive imaging technology for molecular detection of cancer and physiological change, and Infotonics Technology Center announced the execution of their Collaborative Research and Development Agreement for the development of the Mediscience "Compact Photonic Explorer" (CPE), or "pill camera," to be commercialized by Mediscience for medical and non-medical applications. The initial project effort will utilize the Mediscience Intellectual Property to detect cancer and monitor physiological body functions throughout the digestive tract with a disposable swallowable pill. The Parties will collaborate in the development of Mediscience commercially viable miniature devices making use of ultraviolet light to diagnose the health of living tissue; and remotely monitoring the health/status of various medical and non-medical environments, e.g., the detection of various types of cancer and monitoring of physiological body functions, the sensing of biological and chemical species such as bacteria and pollutants among others in the human body; and other non-medical applications. The proof-of-concept funded research for the (CPE), led by Dr. Robert Alfano and his team at City University of New York (CUNY), has been successfully based upon an on-going four-year multidisciplinary/multi-institutional commitment to develop miniature devices that use light to remotely monitor the health of various environments in on-going collaboration with researchers at Cornell, SUNY Albany, SUNY Binghamton, RPI, Rochester Institute of Technology, the University of Rochester, and Boston University. Mediscience President Michael Engelhart stated, "Each Party's existing experience and knowledge base will be important in achieving the successful performance of the objectives of this Agreement, and each Party is expected to contribute from its experience and knowledge to maximize the commercial benefits from the Research. We have an agreement that aligns our interests and are confident in our mutual capabilities in implementing a process that leads to significant economic value. We are particularly pleased that Infotonics has accepted a one million share position in Mediscience for its $2 million contribution to the project with a 6 yr. warrant to acquire an additional million shares at an exercise of $3,00 per share. Mediscience Chairman/CEO Peter Katevatis Esq. stated, "This Agreement and managements desire to move forward to commercialization provides a timely opportunity to jointly explore our proprietary non-invasive imaging technology and develop the potential value and return to ourshareholders that we seek." Les Fritzemeier, Infotonics' Director of Business Development and Government Programs, said such an agreement is "a milestone" for the Center, since the (CPE) stems from collaborative, Infotonics-funded research at eight universities over the past two years. "This is a prime example of the role the Infotonics Center can play in moving innovations into the marketplace to drive economic growth." Infotonics Technology Center Inc. (Infotonics) is a consortium, not-for-profit Corporation, that operate New York State's Center of Excellence in Photonics and Microsystems. The Rochester NY State Regional Photonics Cluster is an industrial partner, and academic participants include some 20 New York State colleges and Universities. Infotonics' goal is to establish a unique, world-class research and development facility to enable rapid commercialization of new products, with major benefits to the region, including creation of jobs and attraction and development of new companies and investment revenue. The Infotonics Technology Center Inc. (Infotonics) operates New York State's Center of Excellence in Photonics and Microsystems. It is a not for profit consortium with founding participants Corning, Inc., Eastman Kodak Company, and Xerox Corporation. About Mediscience Technology Mediscience Technology Corporation and its New York subsidiary, Medi-photonics Development Company LLC, are engaged in the design, development and commercialization of medical devices that detect cancer and physiological change using frequencies of light that are emitted, scattered and absorbed to distinguish malignant, Pre-cancerous, or benign tissues from normal tissues. Mediscience's exclusive protected noninvasive technology combines the advantages of real-time results with enhanced diagnostic sensitivity and specificity compared with other methods of cancer detection. See Web sites:
www.infotonics.org/ResearchProjects/CompactPhotonicExplorers.asp See Mediscience 8-K filing dated September 8 , 2004 See New England Journal of Medicine 7-29-04 (general results of developing capsule endoscopic technology) INVESTOR NOTICE: Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the parties/company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include among other things, the availability of financing, the parties/ company's ability to implement its long-range business plan for various applications of its technology; the company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary US regulatory clearances applicable to applications of the company's technology; and management of growth and other risked and uncertainties that may be detailed from time to time in the parties/company's reports filed with the Securities and Exchange Commission. This disclosure is intended to satisfy: SEC Section 6, 6.01 Regulation FD, disclosure and Section 7 and 7.0 as well as all applicable and presently effective Sarbanes-Oxley disclosure requirements under Regulation G.
Copyright Business Wire 2004 INFOTONICS TECHNOLOGY CENTER AND MEDI-PHOTONICS DEVELOPMENT COMPANY LLC ANNOUNCED THEIR INTENT TO AGREE TO JOINTLY DEVELOP THE "COMPACT PHOTONIC EXPLORER". INFOTONICS IS A CONSORTIUM THAT INCLUDES CORNING, INC., EASTMAN KODAK COMPANY, AND XEROX CORPORATION, AND SEVERAL NEW YORK STATE UNIVERSITIES. INFOTONICS IS A WORLD-CLASS RESEARCH AND DEVELOPMENT FACILITY ESTABLISHED TO ENABLE THE RAPID COMMERCIALIZATION OF NEW HIGH TECH PRODUCTS. CHERRY HILL, N.J.--(BUSINESS WIRE)--Sept. 8, 2004-- Infotonics Technology Center and Medi-photonics Development Company LLC, a subsidiary of Cherry Hill New Jersey-based Mediscience Technology Corp. (MTC), (OTCBB:MDSC), a developer of proprietary non-invasive imaging technology for molecular detection of cancer and physiological change, announced their intent to agree to jointly develop the "Compact Photonic Explorer" (CPE), or "pill camera," for medical and non-medical applications. The parties initial focus of the project is developing a (CPE) that would detect cancer and monitor body functions. The proof-of-concept research for the (CPE), led by Dr. Robert Alfano and his team at City University of New York (CUNY), has been successful based upon an on-going four-year multidisciplinary/multi-institutional effort to develop miniature devices that use light to remotely monitor the health of various environments in collaboration with researchers at Cornell, SUNY Albany, SUNY Binghamton, RPI, Rochester Institute of Technology, the University of Rochester, and Boston University. Infotonics Technology Center Inc. (Infotonics) is a consortium whose founding participants include Corning, Inc., Eastman Kodak Company, and Xerox Corporation, a not-for-profit corporation that operates New York State's Center of Excellence in Photonics and Microsystems. Mediscience President Michael Engelhart stated, "the first goal of a joint development initiative would be to create an ingestible photonic pill that would enable physicians to detect early stage cancer of the complete auto-digestive tract. Such a non-invasive device would lead to reduced mortality and health care costs, and would significantly increase the number of people who could be screened for this type of cancer; further an agreement between Medi-photonics and Infotonics would be a synergistic and strategic fit leveraging the Center's unique nanotechnology capabilities and resources to provide our customers and partners with an exceptional state of the art competitive advantage." Mediscience Chairman Peter Katevatis Esq. stated, "This project has and will continue to enhance Mediscience proprietary non-invasive imaging technology for molecular detection of cancer and physiological change and the Company's desire to move forward to commercialize its patented Optical Biopsy technology as it also prepares and initiates clinical trials for cervical cancer applications." Les Fritzemeier, Infotonics' Director of Business Development and Government Programs, said such an agreement will be "a milestone" for the Center, since the (CPE) stems from collaborative, Infotonics-funded research at eight universities over the past two years. "This is a prime example of the role the Infotonics Center can play in moving innovations into the marketplace to drive economic growth." Engelhart and Fritzemeier noted that medical applications for a photonic pill device would be just a starting point. Non-medical applications could involve sensing biological and chemical species, such as bacteria and pollutants, or for surveillance to determine the safety of compact structures and devices. The Infotonics Technology Center Inc. (Infotonics) is a not-for-profit corporation that operates New York State's Center of Excellence in Photonics and Microsystems. Infotonics is structured as a consortium whose founding participants include Corning, Inc., Eastman Kodak Company, and Xerox Corporation. The Rochester Regional Photonics Cluster is an industrial partner, and academic participants include some 20 New York State colleges and universities. Infotonics' goal is to establish a unique, world-class research and development facility to enable rapid commercialization of new products. This initiative will provide major benefits to the region, including creation of jobs and attraction of new companies and investment revenue. About Mediscience Technology Mediscience Technology Corporation and its New York subsidiary, Medi-photonics Development Company LLC, is engaged in the design, development and commercialization of medical devices that detect cancer and physiological change using frequencies of light that are emitted, scattered and absorbed to distinguish malignant, precancerous, or benign tissues from normal tissues. Mediscience's exclusive protected noninvasive technology combines the advantages of real-time results with enhanced diagnostic sensitivity and specificity compared with other methods of cancer detection. See Web sites:
www.infotonics.org/ResearchProjects/CompactPhotonicExplorers.asp See Mediscience 8-K filing dated September 8 , 2004 See New England Journal of Medicine 7-29-04 (general results of developing capsule endoscopic technology) INVESTOR NOTICE: Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the parties/company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include among other things, the availability of financing, the parties/ company's ability to implement its long-range business plan for various applications of its technology; the company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary US regulatory clearances applicable to applications of the company's technology; and management of growth and other risked and uncertainties that may be detailed from time to time in the parties/company's reports filed with the Securities and Exchange Commission. This disclosure is intended to satisfy: SEC Section 6, 6.01 Regulation FD, disclosure and Section 7 and 7.0 as well as all applicable and presently effective Sarbanes-Oxley disclosure requirements under Regulation G.
MEDISCIENCE TECHNOLOGY CORP. PREVENTS UNAUTHORIZED LISTING OF COMPANY STOCK ON BERLIN-BREMEN STOCK EXCHANGE CHERRY HILL, N.J., Aug 2, 2004 (BUSINESS WIRE) - Mediscience Technology Corp. (OTC:MDSC) announced today that it has successfully prevented the unauthorized listing of the Company's stock on the Berlin-Bremen Stock Exchange. Recent public announcements by a substantial number of other U.S. publicly-traded companies indicate that they have been listed on the Berlin exchange without their permission. Financial media reports speculate these unauthorized listings may be part of an effort to avoid United States Securities and Exchange Commission restrictions against "naked short selling." Such practices may allow for market manipulation by selling non-existent shares of stock in an effort to force the price down. Mediscience discovered the attempted listing of its Shares on the Berlin-Bremen Exchange without its approval, consent, or knowledge and immediately initiated contact with the Berlin-Bremen Stock Exchange demanding immediate de-listing of the Company's stock. Berlin-Bremen Stock Exchange legal counsel confirmed effective de-listing and zero trading activity on August 2, 2004. Mediscience believes this prompt action to de-list from the Berlin-Bremen Exchange, will maintain stability in its stock price and avert any potential market manipulation of its shares. INVESTOR NOTICE: Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include among other things, the availability of financing, the company's ability to implement its long-range business plan for various applications of its technology; the company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary US regulatory clearances applicable to applications of the company' technology; and management of growth and other risked and uncertainties that may be detailed from time to time in the company's reports filed with the Securities and Exchange Commission. This disclosure is intended to satisfy: SEC Section 6, 6.01 Regulation FD, disclosure and Section 7 and 7.0 as well as all applicable and presently effective Sarbanes-Oxley disclosure requirements under Regulation G. JUNE 15, 2004: NEW CD-ROM FROM OPTICAL SOCIETY OF AMERICA OFFERS COMPREHENSIVE COLLECTION OF PAPERS ON BIOMEDICAL OPTICAL BIOPSY Dr. Robert R. Alfano, Director of City College’s Institute for Ultrafast Spectroscopy and Lasers, is the senior editor of a new CD-ROM entitled Biomedical Optical Biopsy that was released recently by the Optical Society of America (OSA). The CD-ROM is an important collection of over 300 classic articles from the earliest to the most recent on the subject of optical biopsy. Optical biopsy involves the use of light and photonic technology to diagnose cancer without removing tissue from the body. It replaces invasive cancer detection techniques to determine its extent and assist in surgery and diagnostics. Biomedical Optical Biopsy is an especially valuable resource for undergraduate and graduate students who are embarking on research involving optical biopsy, as well as for scientists, engineers and physicians in the field. The CD-ROM is fully searchable by subject, keyword or author’s name. In addition to reprinted papers Biomedical Optical Biopsy contains lists of patents, books on optical biopsy, journals, resources for manuscript preparation and other useful information. Among the numerous subject areas covered in Biomedical Optical Biopsy are the following: Fluorescence Biopsy, Raman Biopsy Techniques, Time-Resolved Techniques, Optical Coherence Reflectometry and Tomography, Confocal Microscopy, and Nonlinear Optical Imaging Techniques such as Second Harmonic Generation and Multiphoton Excitation. Dr. Alfano is Distinguished Professor of Science and Engineering at CCNY. His co-editor is Dr. Barry Masters, a leading authority on multi-photon imaging. "Biomedical Optical Biopsy offers a host of outstanding papers from the beginning of the field to the present by a wide-range of authors in a convenient, compact, easily searchable form," Dr. Alfano said. The papers were selected on the basis of the innovative quality of the experimental or theoretical work, their educational value and their impact on the field. "Papers were chosen because of their contributions in one or more of the following areas: pioneering work; sources of data; experimental method, and design technique," Dr. Alfano added. The new CD-ROM will be especially useful to those who are interested in the field and want a guided tour through emerging areas of research. To order the CD-ROM Biomedical Optical Biopsy from the Optical Society of America please go to www.osa.org/pubs/bookstore2 MEDISCIENCE TECHNOLOGY CORP. ANNOUNCES PROJECT AGREEMENT FOR DEVELOPMENT OF CANCER DETECTION AND DIAGNOSIS DEVICE WITH RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK CHERRY HILL, N.J., (May 2, 2004) - MediPhotonics Development LLC a wholly owned New York Subsidiary of Mediscience Technology Corp (otc-mdsc)., announced that on May 1, 2004 it entered into a Project Agreement with The Research Foundation of City University of New York. Mediscience Technology of Cherry Hill, New Jersey, is a developer of imaging technology for molecular detection of cancer and physiological change. President and COO Michael Engelhart stated "this Project Agreement provides the Company a clear path in its intent to commercialize the CD Ratiometer for detecting and diagnosing cancers of the cervix, mouth, esophagus and gastro intestinal tract and other potential applications that are compatible with current state of the art computer hardware and operating systems". Engelhart added, "We expect to have a completed device by November 30, 2004". RF-CUNY will complete production of the improved CD-Ratiometer instrument(s) by which Mediscience will seek approval by the United States Food and Drug Administration ("FDA") for marketing in the U.S. RFCUNY will apply its research and development to deliver an updated CD-Ratiometer and associated technology to be used in Mediscience Optical Biopsy, including the testing of the Mediscience CD-Ratiometer on ex vivo human tissue specimens. Under the specific terms of the Project agreement, Mediscience is granted an exclusive world-wide license, with the right to grant sublicenses, to make, use or sell all patented imaging product technology for molecular detection of cancer and physiological change Dr. Robert Alfano "The Project agreement and present world-wide Mediscience Patent positioning supports and extends the Mediscience core technology in Optical Biopsy, expanding, continuing and maintaining its leadership in the Optical Biopsy field". INVESTOR NOTICE: Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include among other things, the availability of financing, the company's ability to implement its long-range business plan for various applications of its technology; the company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary US regulatory clearances applicable to applications of the company' technology; and management of growth and other risked and uncertainties that may be detailed from time to time in the company's reports filed with the Securities and Exchange Commission. This disclosure is intended to satisfy: SEC Section 6, 6.01 Regulation FD, disclosure and Section 7 and 7.0 as well as all applicable and presently effective Sarbanes-Oxley disclosure requirements under Regulation G.
MEDISCIENCE TECHNOLOGY CORP. NAMES ROBERT G. PINCO TO ADVISORY COUNCIL CHERRY HILL, N.J., (April 14, 2004) - Mediscience Technology Corp. (MTC), (OTCBB:MDSC) of Cherry Hill, New Jersey, announced today that Robert G. Pinco Esquire has joined the company's advisory council. Mr. Pinco is co-chairman of the BioMedical/FDA Practice and head of the firm's biotechnology group practice of Buchanan Ingersoll, a leading international law firm with specialization in the biotechnology sector. As a member of Mediscience's advisory council, Mr. Pinco will counsel its management team on matters pertaining to government regulatory approval for many of Mediscience's new products and applications in the U.S. and Europe. Based in Washington, D.C., Mr. Pinco has more than 35 years of experience in the pharmaceutical sector. As a former director of the Over-the-Counter Drug Review of the FDA, he directed a massive review of more than 400,000 non prescription drugs, the largest, most complex project ever undertaken by that agency. He also held positions as White House Associate Counsel; Associate General Counsel, Special Action Office for Drug Abuse Prevention with the Drug Enforcement Administration (DEA); Assistant U.S. Attorney for the District of Columbia and as a pharmacist. Mr. Pinco is an Adjunct Associate Professor of Pharmacy Practices and Administrative Sciences at University of Maryland. He is also a member of the University of Connecticut, School of Pharmacy, Board of Advisors. "Bob Pinco's professionalism and expertise in effectively navigating new products through the FDA and Buchanan Ingersoll's vast resources in the biotechnology sector, are invaluable to Mediscience as we prepare to introduce new medical screening and diagnostic devices to the U.S. marketplace," said Michael Engelhart President Chief Operating Officer of Mediscience. About Mediscience Technology Corp. Based in Cherry Hill, New Jersey, and New York City Mediscience Technology Corp., is engaged in the design, development, manufacturing and marketing of screening and diagnostic medical devices that detect cancer using light induced native tissue fluorescence spectroscopy to distinguish between malignant and normal or benign tissue. Visit www.medisciencetech.com. Forward-Looking Statements The statements made in this press release discussing the potential of Mediscience's products and the potential for regulatory approval are forward looking statements within the meaning of the Private securities Litigation Reform Act of 1995 (the "Act"). Additionally words such as "seek," "intend," "believe," "plan," "estimate," "expect," "anticipate" and other similar expressions are forward-looking statements within the meaning of the Act. Some or all of the results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include, but are not limited to, Mediscience's raising sufficient funds to support its development, marketing efforts and corporate overhead, its ability to attract technical employees, the ability of Mediscience's management to grow its business with limited assistance and its ability to meet a variety of regulatory requirements. Mediscience has no duty and undertakes no obligation to update such statements.
MEDISCIENCE TECHNOLOGY CORP. (OTC-MDSC) ANNOUNCES THE SUCCESSFUL CLOSING OF A $1.5 MILLION DOLLARS PRIVATE PLACEMENT AS OF FEBRUARY 1, 2004 CHERRY HILL, N.J., (Feb 2, 2004) - Mediscience Technology Corp. (MTC), (OTCBB:MDSC) of Cherry Hill, New Jersey, a developer of imaging technology for molecular detection of cancer and physiological change, announced that on February 1, 2004 it privately closed an SEC Reg. “D” Private Placement for a net cash infusion to the Company of $1.5 Million dollars. Investment basis: Mediscience Convertible Preferred Shares each priced at $25,000. No warrants or interest obligation attached, the Convertible Preferred shares may be converted into 100,000 shares of Mediscience common shares at the sole discretion of Mediscience subsequent to February 17, 2004. The company has agreed to file an SEC re-sale shelf registration S-3 within a period of 6 months or sooner after February 17, 2004. Chairman/CEO Peter Katevatis stated “that this funding will allow the company to move positively forward in our intent and effort to commercialize our Optical Biopsy technology”. INVESTOR NOTICE: Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include among other things, the availability of financing, the company's ability to implement its long-range business plan for various applications of its technology; the company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary US regulatory clearances applicable to applications of the company'technology; and management of growth and other risked and uncertainties that may be detailed from time to time in the company's reports filed with the Securities and Exchange Commission. This disclosure is intended to satisfy: SEC Section 6, 6.01 Regulation FD, disclosure and Section 7 and 7.0 as well as all applicable and presently effective Sarbanes-Oxley disclosure requirements under Regulation G. SOURCE: Mediscience Technology Corp. Mediscience Technology Corp., Cherry Hill Michael Engelhart, mengelhart@thmgroup.com or Peter Katevatis Esq. metpk@aol.com |
||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||
|
|
| Copyright © 2004 Mediscience Technology Corp. | Contact Us |
|
|
|
|